Veterinary Drug terms — page 9 | HESTIA Glossary

Browse all 1,061 veterinary drug terms HESTIA uses to describe agricultural data — with definitions and synonyms. Free and open.

Drospirenone (2'S,6R,7R,8R,9S,10R,13S,14S,15S,16S)-1,3',4',6,7,8,9,10,11,12,13,14,15,16,20,21-Hexadecahydro-10,13-dimethylspiro[17H-dicyclopropa[6,7:15,16]cyclopenta[a]phenanthrene-17,2'(5'H)-furan]-3,5'(2H)-dione; Drospirenone [USAN:USP:INN:BAN]; BRN 4765500
Duroquinone 2,3,5,6-Tetramethyl-2,5-cyclohexadiene-1,4-dione; Duroquinone; 527-17-3; Tetramethyl-1,4-benzoquinone; Tetramethyl-p-benzoquinone; Tetramethylquinone; 2,3,5,6-tetramethylcyclohexa-2,5-diene-1,4-dione; 2,3,5,6-Tetramethyl-1,4-benzoquinone; Tetramethyl-p-quinone; 2,3,5,6-Tetramethylbenzoquinone; p-Benzoquinone, tetramethyl-; p-Benzoquinone, 2,3,5,6-tetramethyl-; 2,5-Cyclohexadiene-1,4-dione, 2,3,5,6-tetramethyl-; 2,3,5,6-Tetramethyl-p-benzoquinone; NSC 2068; CCRIS 2989; p-Benzoquinone, tetramethyl-, semiquinone; UNII-X0Q8791R69; EINECS 208-409-8; 2,3,5,6-tetramethyl-2,5-cyclohexadiene-1,4-dione; 2,3,5,6-Tetramethylbenzo-1,4-quinone; 2,3,5,6-tetramethyl-[1,4]benzoquinone; AI3-61045; CHEBI:42023; WAMKWBHYPYBEJY-UHFFFAOYSA-N; X0Q8791R69; tetramethylcyclohexa-2,5-diene-1,4-dione; Duroquinone, 97%; tetramethylbenzoquinone; tetramethyl benzoquinone; SCHEMBL58325; 2,5,6-Tetramethylbenzoquinone; ACMC-209l13; CHEMBL151604; CTK4J6342; ZINC87597; DTXSID50200659; NSC2068; 2,5,6-Tetramethyl-p-benzoquinone; HMS1667I20; BB_NC-00704; NSC-2068; p-Benzoquinone,3,5,6-tetramethyl-; ACM527173; ANW-31525; BBL027347; STL356801; 2,5,6-Tetramethyl-1,4-benzoquinone; AKOS004903738; 2,4-dione, 2,3,5,6-tetramethyl-; DB01927; FCH1114765; MCULE-4663973266; KS-0000151V; AC-27924; AS-67719; LS-56285; M949; SC-70899; 2,3,5,6-Tetramethylbenzo-1,4-quinone #; TR-030621; FT-0625631; ST45022058; p-Benzoquinone, 2,3,5,6-tetramethyl- (8CI); Q2423089; 2,5-Cyclohexadiene-1,4-dione,2,3,5,6-tetramethyl-; Duroquinone, Standard for quantitative NMR, TraceCERT(R); InChI=1/C10H12O2/c1-5-6(2)10(12)8(4)7(3)9(5)11/h1-4H; Duroquinone; AI3-61045
Dydrogesterone (9beta,10alpha)-Pregna-4,6-diene-3,20-dione; dydrogesterone; Isopregnenone; 152-62-5; Hydrogesterone; Duphaston; Hydrogestrone; Gestatron; Diphaston; Dufaston; Gynorest; 10alpha-Isopregnenone; Duvaron; Prodel; Retrone; Terolut; Retro-6-dehydroprogesterone; Didrogesterone [DCIT]; Didrogesterone; Dydrogesteronum; delta(6)-Retroprogesterone; 6-Dehydro-retro-progesterone; Dydrogesteronum [INN-Latin]; Dydrogesterona [INN-Spanish]; delta(sup 6)-Retroprogesterone; 9beta,10alpha-Pregna-4,6-diene-3,20-dione; Retroprogesterone, 6-dehydro-; UNII-90I02KLE8K; 6-Dehydro-9beta,10alpha-progesterone; CCRIS 9069; HSDB 3321; EINECS 205-806-8; 9-beta,10alpha-Pregna-4,6-diene-3,20-dione; NSC 92336; (8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-3-one; (9beta,10alpha)-pregna-4,6-diene-3,20-dione; (9-beta,10-alpha)-Pregna-4,6-diene-3,20-dione; Pregna-4,6-diene-3,20-dione, (9beta,10alpha)-; MLS002153947; 90I02KLE8K; CHEBI:31527; 9-beta,10-alpha-Pregna-4,6-diene-3,20-dione; NSC-92336; Dydrogesterona; Dehydrogesterone; DSSTox_CID_2974; DSSTox_RID_76812; DSSTox_GSID_22974; didrogesterona; Duphaston (TN); Gynorest (TN); CAS-152-62-5; MLS002695106; 6-Dehydroretroprogesterone; Dydrogesterone [USAN:INN:BAN:JAN]; 6-Dehydro-9 beta-10 alpha-progesterone; NSC92336; NCGC00016413-01; Dydrogesterone [USAN:USP:INN:BAN:JAN]; 6-Dehydro-9.beta.,10.alpha.-progesterone; Prestwick0_000671; Prestwick1_000671; Prestwick2_000671; Prestwick3_000671; Pregna-4,6-diene-3,20-dione, (9b,10a)-; .DELTA.6-Retroprogesterone; SCHEMBL37703; BSPBio_000761; SPBio_002682; 9beta,10alpha-Pregna-4,6-diene-3,20-dione (8CI); BPBio1_000839; GTPL2878; CHEMBL1200853; DTXSID1022974; HY-B0257A; 9.beta.,6-diene-3,20-dione; Dydrogesterone (JP17/USP/INN); JGMOKGBVKVMRFX-HQZYFCCVSA-N; HMS1570G03; HMS2097G03; HMS2230C10; HMS3714G03; 9-.beta.,6-diene-3,20-dione; BCP12878; ZINC3875998; Tox21_110429; AKOS015895532; Tox21_110429_1; CCG-220671; CS-2434; DB00378; GS-6735; NCGC00179445-01; NCGC00179445-03; NCGC00179445-04; CC-27423; I033; SC-71085; SMR001233286; LS-118418; AB00513884; (9?,10?)-Pregna-4,6-diene-3,20-dione; D01217; Pregna-4,20-dione, (9.beta.,10.alpha.)-; AB00513884_04; 152D625; C-23776; SR-01000841256; Q4161380; SR-01000841256-2; W-108050; BRD-K68620903-001-03-1; BRD-K68620903-001-11-4; Pregna-4,6-diene-3,20-dione, (9-beta,10-alpha)-; Pregna-4,6-diene-3,20-dione, (9-beta,10-alpha)- (9CI); (1R,2S,10S,11S,14S,15S)-14-acetyl-2,15-dimethyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-6,8-dien-5-one; (8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,8,9,10,11,12,13,14,15,16,17-dodecahydro-3H-cyclopenta[a]phenanthren-3-one; (8S,9R,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-8,9,10,11,12,13,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3(2H)-one; Dydrogesterone; 6-Dehydro-9beta,10alpha-progesterone
Ebselen 2-Phenyl-1,2-benzisoselenazol-3(2H)-one; ebselen; 60940-34-3; 2-Phenyl-1,2-benzisoselenazol-3(2H)-one; 2-phenyl-1,2-benzoselenazol-3-one; Ebselene; Ebseleno; Ebselenum; SPI-1005; Ebselene [French]; Ebselenum [Latin]; Ebselen [INN]; Ebseleno [Spanish]; PZ 51; 2-phenylbenzo[d][1,2]selenazol-3(2H)-one; Harmokisane; PZ-51; C13H9NOSe; DR-3305; MLS000028488; UNII-40X2P7DPGH; CCRIS 3714; PZ51; 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl-; 2-Phenyl-1,2-benzisoselenazolin-3-one; SMR000058445; 2-phenyl-1,2-benzoisoselenazol-3(2H)-one; CHEMBL51085; NSC 639762; DR 3305; Prestwick_1057; RP 60931; SPI-3005; Prestwick0_000740; Prestwick1_000740; Prestwick2_000740; Prestwick3_000740; Spectrum2_001441; Spectrum3_000799; Spectrum4_000445; Spectrum5_001713; Lopac-E-3520; NSC639762; 40X2P7DPGH; Lopac0_000541; NCGC00015412-06; BSPBio_000700; BSPBio_001342; BSPBio_002538; CPD000058445; KBioGR_000062; KBioGR_000830; KBioSS_000062; DivK1c_000951; SPBio_001301; SPBio_002639; CAS-60940-34-3; MLS001148646; BPBio1_000770; BCBcMAP01_000149; CHEBI:77543; HMS502P13; KBio1_000951; KBio2_000062; KBio2_002630; KBio2_005198; KBio3_000123; KBio3_000124; KBio3_001758; NINDS_000951; DYEFUKCXAQOFHX-UHFFFAOYSA-N; E 3520; Bio2_000062; Bio2_000542; HMS1361D04; HMS1570C22; HMS1791D04; HMS1989D04; HMS2052N09; DR3305; NSC-639762; AC-1124; IDI1_000951; IDI1_033812; QTL1_000035; NCGC00015412-01; NCGC00015412-02; NCGC00015412-03; NCGC00015412-13; NCGC00024072-03; NCGC00024072-04; NCGC00024072-05; NCGC00178610-01; NCGC00178610-02; NCGC00178610-03; 2-phenyl-1,2-benzoselenazol-3(2h)-one; AK115695; LS-33527; SAM001247071; AB00053217; EU-0100541; MLS-0003066.0001; BRD-K29359156-001-06-1; SR-01000003081; AC1L1FDW; CID3194; CCG-39161; Ebselen (C5); Ebselen, 99%; nchembio.109-comp1; Opera_ID_1643; Ebselen, cysteine modifier; cid_3194; DSSTox_CID_25150; DSSTox_RID_80704; C042986; DSSTox_GSID_45150; SCHEMBL33829; MLS001424261; MLS006010108; E3520_SIGMA; I09-1611; DTXSID7045150; BDBM34233; CTK7H1817; GTPL10583; CHEBI:175507; HMS2097C22; HMS2235A11; HMS3394N09; HMS3402D04; HMS3649O05; HMS3714C22; KUC112559N; Pharmakon1600-01501188; BCP17134; EX-A1447; KS-00000G4G; Tox21_110140; 2-Phenyl-benzo[d]isoselenazol-3-one; BN0569; DAP001372; GP4285; MFCD00210937; NSC757883; s6676; AKOS015898841; API0002512; CS-5534; DB12610; LP00541; NC00431; NSC-757883; SDCCGSBI-0050524.P004; TRA0091838; KSC-325-014; NCGC00015412-04; NCGC00015412-05; NCGC00015412-07; NCGC00015412-08; NCGC00015412-09; NCGC00015412-10; NCGC00015412-11; NCGC00015412-12; phenyl-1,2-benzisoselenazol-3(2H)-one; 2-phenyl-1,2-benzisoselazol-3(2H)-one; HY-13750; SBI-0050524.P003; 2-phenyl-1,2-benzisoselenazole-3(2H)-one; AB0020911; AX8127093; DB-072873; 2-phenyl-1,2-benzoisoselenazole-3(2H)-one; E0946; FT-0759332; V1941; 2-phenyl-1,2-benzoisoselenazole-3-(2H)-one; 2-Phenyl-benzo[d]isoselenazol-3-one(Ebselen); AB00053217_25; 940E343; Q5332073; SR-01000003081-2; SR-01000003081-7; SR-01000003081-8; BRD-K29359156-001-23-6; SR-01000003081-10; SR-01000003081-14; Ebselen; CCRIS 3714
Edaravone 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; edaravone; 89-25-8; 1-Phenyl-3-methyl-5-pyrazolone; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; Norphenazone; Radicut; MCI-186; Methylphenylpyrazolone; Developer Z; Norantipyrine; Phenylmethylpyrazolone; C.I. Developer 1; Phenyl methyl pyrazolone; Radicava; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl-; 1-Phenyl-3-methylpyrazolone; 3-Methyl-1-phenyl-1H-pyrazol-5(4H)-one; CI Developer 1; 1-Phenyl-3-methylpyrazolone-5; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; 3-Methyl-1-phenylpyrazol-5-one; 3-Methyl-1-phenyl-2-pyrazoline-5-one; NCI-C03952; 2-Pyrazolin-5-one, 3-methyl-1-phenyl-; 5-Pyrazolone, 3-methyl-1-phenyl-; NSC 12; Edaravone (MCI-186); 1-Fenyl-3-methyl-2-pyrazolin-5-on; CCRIS 512; 3-methyl-1-phenyl-4,5-dihydro-1H-pyrazol-5-one; CHEBI:31530; HSDB 4102; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; NSC-2629; EINECS 201-891-0; MFCD00003138; NSC-26139; BRN 0609575; AI3-03557; MLS000069602; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE (MCI-186); QELUYTUMUWHWMC-UHFFFAOYSA-N; 3-methyl-1-phenyl-2-pyrazolin-5one; NCGC00164015-01; SMR000059020; DSSTox_CID_1130; DSSTox_RID_75961; DSSTox_GSID_21130; Monopyrazolone; WLN: T5NMV DHJ BR& E1; 1-Phenyl-3-methyl-2-pyrazolin-5-on; CAS-89-25-8; Radicut (TN); 3-Methyl-1-phenyl-2-pyrazolin-5-one, 99%; 3H-Pyrazol-3-one,4-dihydro-5-methyl-2-phenyl-; SR-01000000135; Radicava (TN); (MCI-186); Radicut; MCI-186; CDS1_000986; PubChem13301; Spectrum_000267; Tocris-0786; Edaravone [USAN:INN]; Maybridge1_005738; Opera_ID_1057; Spectrum2_001574; Spectrum3_000971; Spectrum4_001091; Spectrum5_001217; M0687; EC 201-891-0; SCHEMBL4704; Antipyrine related compound a; BSPBio_001235; BSPBio_002601; KBioGR_000575; KBioGR_001502; KBioSS_000575; KBioSS_000747; AE-641/00371017; KSC448M1D; MLS001146878; MLS002415675; MLS006011753; DivK1c_001018; DivK1c_002026; SPECTRUM1503635; SPBio_001508; CHEMBL290916; Edaravone (USAN/JP17/INN); DTXSID9021130; BCBcMAP01_000127; CTK3E8611; HMS503K17; HMS557M18; KBio1_001018; KBio2_000575; KBio2_000747; KBio2_003143; KBio2_003315; KBio2_005711; KBio2_005883; KBio3_001029; KBio3_001030; KBio3_001821; NSC2629; NINDS_001018; BCPP000246; Bio1_000438; Bio1_000927; Bio1_001416; Bio2_000448; Bio2_000928; HMS1362M17; HMS1792M17; HMS1990M17; HMS2234M19; HMS3266F04; HMS3403M17; HMS3411L05; HMS3654L15; HMS3675L05; Pharmakon1600-01503635; ACT07289; BCP26336; HY-B0099; KS-00000X6I; NSC26139; Tox21_112077; Tox21_201747; Tox21_302819; BBL011741; BDBM50200541; CCG-39352; NSC758622; s1326; STK201315; ZINC18203737; AKOS000313817; Tox21_112077_1; AC-4745; BCP9000635; CS-1832; DB12243; LS-1892; MCI-186, Radicut, 89-25-8; NE10266; NSC-758622; RTR-028045; SB19128; IDI1_001018; IDI1_002203; 1-PEHNYL-3-METHYL-5-PYRAZALONE; NCGC00018218-01; NCGC00018218-02; NCGC00018218-03; NCGC00018218-04; NCGC00018218-05; NCGC00018218-06; NCGC00018218-07; NCGC00018218-08; NCGC00018218-10; NCGC00018218-17; NCGC00022665-02; NCGC00022665-04; NCGC00022665-05; NCGC00022665-06; NCGC00256515-01; NCGC00259296-01; 4CA-0486; AK128848; SC-13582; ST012744; SBI-0051836.P002; AB2000046; DB-002517; ST2410773; TR-028045; AM20060748; FT-0608243; SW148216-2; 5-methyl-2-phenyl-2,4-dihydro-3-pyrazolone; 5-methyl-2-phenyl-2,4-dihydropyrazol-3-one; 3-Methyl-1-phenyl-2-pyrazoline-5-one, 99%; 4E-901; 5-methyl-2-phenyl-2,4-dihydro-pyrazol-3-one; C13008; D01552; AB00375776_14; AB00375776_15; 2 4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 2,4-dihydro-2-phenyl-5-methyl-3H-pyrazol-3-one; Q335099; Q-200386; SR-01000000135-2; SR-01000000135-3; SR-01000000135-5; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one #; BRD-K35458079-001-04-2; BRD-K35458079-001-12-5; BRD-K35458079-001-23-2; Z50145861; F0391-0021; 3-Methyl-1-phenyl-2-pyrazoline-5-one, SAJ special grade; 3-Methyl-1-phenyl-2-pyrazoline-5-one, purum, >=98.0% (NT); 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (Edaravone); Phenazone impurity A, European Pharmacopoeia (EP) Reference Standard; Antipyrine Related Compound A, United States Pharmacopeia (USP) Reference Standard; InChI=1/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H; C.I. Developer 1
Ellagic acid 2,3,7,8-Tetrahydroxy[1]benzopropyrano[5,4,3-cde][1]benzopyran-5,10-dione; Ellagic acid; C.I. 55005
Emodin 1,3,8-Trihydroxy-6-methyl-9,10-anthracenedione; emodin; 518-82-1; Emodol; Frangula emodin; Schuttgelb; Rheum emodin; Frangulic acid; 1,3,8-trihydroxy-6-methylanthracene-9,10-dione; 3-Methyl-1,6,8-trihydroxyanthraquinone; Archin; Persian Berry Lake; 1,3,8-Trihydroxy-6-methylanthraquinone; 6-Methyl-1,3,8-trihydroxyanthraquinone; 9,10-Anthracenedione, 1,3,8-trihydroxy-6-methyl-; 1,3,8-Trihydroxy-6-methyl-9,10-anthraquinone; C.I. Natural Yellow 14; 1,3,8-Trihydroxy-6-methyl-9,10-anthracenedione; 4,5,7-Trihydroxy-2-methylanthraquinone; UNII-KA46RNI6HN; C.I. 75440; NSC 408120; NSC 622947; CCRIS 3528; HSDB 7093; Anthraquinone, 1,3,8-trihydroxy-6-methyl-; EINECS 208-258-8; NSC408120; KA46RNI6HN; BRN 1888141; AI3-38286; CHEMBL289277; Anthraquinone, 6-methyl-1,3,8-trihydroxy-; CHEBI:42223; 1,3,8-Trihydroxy-6-methylanthra-9,10-quinone; RHMXXJGYXNZAPX-UHFFFAOYSA-N; Emodin-d4; NSC622947; AK160242; 1,3,8-tri-hydroxy-6-methyl-anthra-quinone; Emodin, 95%, tech.; DSSTox_CID_5231; DSSTox_RID_77709; 6-Methyl-1,3,8-trihydroxy-9,10-anthracenedione; DSSTox_GSID_25231; EMO; Q-100581; 9,10-Anthracenedione, 1,3,8-trihydroxy-6-methyl- (9CI); 1,8-Trihydroxy-6-methylanthraquinone; CAS-518-82-1; SMR000326798; SR-01000075615; Embodin; Emdoin; rheum emodium; Frangula-emodin; Rheum-emodin; Frangulinic acid; 3bqc; persian b erry lake; Emodin,(S); Spectrum_001954; 1f0q; 3ed0; SpecPlus_000332; Spectrum2_000895; Spectrum3_000742; Spectrum4_001757; Spectrum5_000614; Lopac-E-7881; Emodin, analytical standard; NCIMech_000049; Lopac0_000552; BSPBio_002324; KBioGR_002234; KBioSS_002508; 1,3,8-trihydroxy-6-methyl-anthracene-9,10-dione; MLS000563068; MLS001066370; MLS004257392; MLS006011712; DivK1c_006428; SCHEMBL177689; SPBio_000710; LS-3; MEGxp0_000460; DTXSID5025231; ACon1_001939; BDBM11318; CTK5B1649; KBio1_001372; KBio2_002500; KBio2_005068; KBio2_007636; KBio3_001544; KS-00000MGZ; HMS2230K22; HMS3261P05; HMS3373B16; HMS3655H22; 1,3,8-trihydroxy-6-methyl-9,10-dihydroanthracene-9,10-dione; ACT03256; BCP18372; TNP00318; ZINC3824868; 9, 1,3,8-trihydroxy-6-methyl-; Tox21_202999; Tox21_303218; Tox21_500552; BS0075; CCG-35263; CE-131; CE0035; GP5697; LMPK13040008; MFCD00001207; s2295; SBB066133; 3-Methyl-1,8-trihydroxyanthraquinone; 4,7-Trihydroxy-2-methylanthraquinone; AKOS003348641; AC-1004; CS-1412; DB07715; KS-5189; LP00552; MCULE-1083063386; NSC-408120; NSC-622947; SDCCGSBI-0050535.P004; Anthraquinone,3,8-trihydroxy-6-methyl-; SMP2_000211; NCGC00015420-01; NCGC00015420-02; NCGC00015420-03; NCGC00015420-04; NCGC00015420-05; NCGC00015420-06; NCGC00015420-07; NCGC00015420-08; NCGC00015420-09; NCGC00091540-01; NCGC00091540-02; NCGC00091540-03; NCGC00091540-04; NCGC00091540-05; NCGC00257090-01; NCGC00260544-01; NCGC00261237-01; 1,3,8-Trihydroxy-6-methyl-anthraquinone; ACM132796522; HY-14393; M371; NCI60_003906; SC-19533; ST055355; AB0015178; AB1010271; AX8006309; TR-018464; 6-methyl-1,3,8-tri-hydroxy-anthra-quinone; E0500; EU-0100552; FT-0606539; N1854; ST24046678; SW219906-1; 1,8-Trihydroxy-6-methyl-9,10-anthraquinone; Emodin, from Frangula bark, >=90% (HPLC); 1,3,8-Tihydroxy-6-methyl-9,10-anthraquinone; A-2578; C10343; E 7881; J10081; K00056; Emodin; 6-Methyl-1,3,8-trihydroxyanthraquinone; 1,3, 8-Trihydroxy-6-methyl-9,10-anthraquinone; 1,3,8-Trihydroxy-6-methylanthra-9,10-quinone #; 1,6,8-trihydroxy-3-methylanthracene-9,10-dione; 518E821; A828825; Anthraquinone, 1,3,8-trihydroxy-6-methyl- (8CI); Q4348178; SR-01000075615-1; SR-01000075615-6; 3-methyl-1,6,8-tris(oxidanyl)anthracene-9,10-dione; BRD-K58685305-001-03-0; 1,3,8-Trihydroxy-6-methyl-9,10-anthracenedione, 9CI; 1,3,8-TRIHYDROXY-6-METHYL-9-10-ANTHRACENEDIONE; Emodin, United States Pharmacopeia (USP) Reference Standard; (RS)-2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione; 120667-83-6; Emodin; C.I. 75440
Enflurane 2-Chloro-1-(difluoromethoxy)-1,1,2-trifluoroethane; enflurane; 13838-16-9; Methylflurether; 2-Chloro-1-(difluoromethoxy)-1,1,2-trifluoroethane; Efrane; Ethrane; Alyrane; Anesthetic 347; 2-Chloro-1,1,2-trifluoroethyl difluoromethyl ether; Compound 347; Anesthetic Compound No. 347; OHIO 347; Enflurano; Enfluranum [INN-Latin]; Enflurano [INN-Spanish]; Ethane, 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoro-; C 347; NSC-115944; Ether, 2-chloro-1,1,2-trifluoroethyl difluoromethyl; EINECS 237-553-4; BRN 1903921; CHEBI:4792; Enflurane [Anaesthetics, volatile]; (+-)-2-Chloro-1,1,2-trifluoroethyl difluoromethyl ether; NCGC00167422-01; Enfluranum; Etran; DSSTox_CID_562; DSSTox_RID_75661; DSSTox_GSID_20562; Ethane, 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoro-, (+-)-; Ethrane (TN); CAS-13838-16-9; Enflurane [USAN:BAN:INN:JAN]; 1-(difluoromethoxy)-2-chloro-1,1,2-trifluoroethane; HSDB 7909; Enflurane [USAN:USP:INN:BAN:JAN]; WLN: GYFXFFOYFF; ACMC-20ai3g; CHEMBL1257; SCHEMBL61712; Enflurane (JP17/USP/INN); GTPL7175; DTXSID1020562; CTK4C1233; JPGQOUSTVILISH-UHFFFAOYSA-N; ACT02934; Tox21_112426; Tox21_200166; 6674AA; ANW-74378; MFCD00069095; NSC115944; SBB090215; AKOS015853043; DB00228; LS-7376; MCULE-8703579240; VZ24151; Ether,1,2-trifluoroethyl difluoromethyl; 4-Chloro-1H,4H-perfluoro(2-oxabutane); NCGC00167422-02; NCGC00257720-01; AS-69470; DB-042426; ST2416656; TR-005081; FT-0625662; ST51041446; C-5062; C07516; D00543; 2-Chloro-1,2-trifluoroethyl difluoromethyl ether; 2-Chloro-1-(difluoromethoxy)-1,2-trifluoroethane; Q416740; SR-01000944966; 2-Chloro-1,1,2-difluoroethane, 1-difluoromethoxy-; SR-01000944966-1; 2- Chloro-1,1,2-trifluoroethyl difluoromethyl ether; 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoro-ethane; Ethane,2-chloro-1-(difluoromethoxy)-1,1,2-trifluoro-; 2-Chloro-1,1,2-trifluoroethyl difluoromethyl ether, AldrichCPR; Benzamide, 2-[[5-chloro-2-[[2-methoxy-4-(4-morpholinyl)phenyl]amino]-4-pyrimidinyl]amino]-N-methyl-; Enflurane; C 347
Enoxolone enoxolone; 471-53-4; GLYCYRRHETINIC ACID; 18-beta-Glycyrrhetinic acid; Glycyrrhetic acid; Uralenic acid; Glycyrrhetin; 18beta-Glycyrrhetinic acid; Jintan; Rhetinic Acid; Arthrodont; Biosone; alpha-Glycyrrhetinic acid; 3beta-Hydroxy-11-oxoolean-12-en-30-oic acid; Enoxolonum [INN-Latin]; Enoxolona [INN-Spanish]; 18-beta-Glycyrrhetic acid; UNII-P540XA09DR; Enoxolone [INN:BAN:DCF]; CCRIS 3962; 18beta-Glycyrrhetic acid; EINECS 207-444-6; NSC 35347; 3-Glycyrrhetinic acid; BRN 2229654; MLS000028748; CHEMBL230006; P540XA09DR; Enoxolone (Glycyrrhetinic acid); (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; CHEBI:30853; 3-beta-Hydroxy-11-oxoolean-12-en-30-oic acid; C30H46O4; Glycyrrhetinate; (3beta)-3-hydroxy-11-oxoolean-12-en-30-oic acid; NSC-35347; 18b-Glycyrrhetic acid; NCGC00017244-03; SMR000058239; DSSTox_CID_669; Olean-12-en-29-oic acid, 3-hydroxy-11-oxo-, (3beta,20beta)-; Glycyrrhetinic acid (JAN); Glycyrrhetinic acid [JAN]; DSSTox_RID_75722; DSSTox_GSID_20669; (2S,4aS,6aS,6bR,8aR,10S,12aS,12bR,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid; Olean-12-en-30-oic acid, 3-beta-hydroxy-11-oxo-; Enoxolonum; (3beta,20beta)-3-Hydroxy-11-oxo-olean-12-en-29-oic acid; EnoxoloGlyciram; (3beta,5beta,14beta)-3-Hydroxy-11-Oxoolean-12-En-29-Oic Acid; 18-beta-Glycyrrhetinic acid, 98+%; 1449-05-4; (5S,8S,15S,18S,1R,2R,10R,14R,20R)-18-hydroxy-1,2,5,8,15,19,19-heptamethyl-13-o xopentacyclo[12.8.0.0<2,11>.0<5,10>.0<15,20>]docos-11-ene-8-carboxylic acid; CAS-471-53-4; SR-01000721867; Enoloxone; NSC-35350; Hidermart (TN); Enoxolone (INN); NCGC00181115-01; CBW; MFCD00003706; Enoxolone (Glycyrrhetin); Opera_ID_1048; SCHEMBL18540; 18 beta-Glycyrrhetintic Acid; 4-10-00-03775 (Beilstein Handbook Reference); MLS001146949; MLS002207101; Enoxolone, Glycyrrhetinic acid; DTXSID9020669; STX-352; CHEBI: 30853; 18beta-Glycyrrhetinic acid, 97%; HMS2233P23; HY-N0180; Tox21_110804; Tox21_112726; Tox21_200799; BDBM50233538; s2296; SBB006496; ZINC19203131; AKOS015960428; AKOS016036757; HMDB: 0011628; AC-1925; AC-8906; API0002854; CCG-208506; CS-W020624; DB13089; GM-1658; KS-1262; LMPR0106150014; LS-7417; MCULE-4676598997; NCGC00017244-04; NCGC00017244-06; NCGC00142473-03; NCGC00258353-01; ST056310; FT-0082445; G0149; ST24038257; 3beta-hydroxy-11-oxoolean-12-en-29-oic acid; C02283; D00156; S00284; 130100-EP2269977A2; 130100-EP2295411A1; 471G534; A827163; (3?)-3-Hydroxy-11-oxoolean-12-en-30-oic acid; 18beta-Glycyrrhetinic acid, purum, >=97.0% (T); Olean-12-en-30-oic acid, 3beta-hydroxy-11-oxo-; Q-201057; Q5948038; SR-01000721867-3; SR-01000721867-4; SR-01000721867-5; SR-01000721867-6; BRD-K96137854-001-17-1; Enoxolone, European Pharmacopoeia (EP) Reference Standard; Olean-12-en-30-oic acid, 3beta-hydroxy-11-oxo- (8CI); 3beta-Hydroxy-11-oxo-18beta,20beta-olean-12-en-29-oic acid; (3alpha,5xi,8alpha,9xi,17alpha,18xi)-3-hydroxy-11-oxoolean-12-en-29-oic acid; (2S,4aS,6aR,6aS,6bR,8aR,10S,12aS,14bR)-2,4a,6a,6b,9,9,12a-heptamethyl-10-oxidanyl-13-oxidanylidene-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; Enoxolone; 18beta-Glycyrrhetinic acid; 3?-Hydroxy-11-oxo-18?,20?-olean-12-en-29-oic acid; enoxolone; Uralenic acid; GLYCYRRHETINIC ACID; Glycyrrhetic acid; Glycyrrhetin; Biosone; 3-Hydroxy-11-oxoolean-12-en-29-oic acid; 3-Glycyrrhetinic acid; .alpha.-Glycyrrhetinic acid; 18.beta.-Glycyrrhetic acid; 18.beta.-Glycyrrhtinic acid; 18.beta.-Glycyrrhetinic acid; NSC35347; NSC35350; 1449-05-4; Olean-12-en-29-oic acid, 3-hydroxy-11-oxo-, (3.beta.,20.beta.)-; Arthrodont; 3.beta.-Hydroxy-11-oxoolean-12-en-30-oic acid; Olean-12-en-30-oic acid, 3.beta.-hydroxy-11-oxo-; NSC-35350; Glyccyrhetic acid; NCGC00181115-01; .beta.-Glycyrrhetic acid; .beta.-Glycyrrhetinic acid; SCHEMBL25465; 10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; 18-.beta.-Glycrrhetinic acid; 18.alpha.-Glycyrrhetinic acid; 18-.beta.-Glycyrrhetinic acid; CHEMBL1863561; Glycyrrhetinic acid, 18 alpha-; MPDGHEJMBKOTSU-UHFFFAOYSA-N; BBL009942; GLYCYRRHETINIC ACID,18 ALPHA; MFCD00066716; STK801355; AKOS005612983; MCULE-3741444667; P.O. 12; NCI60_003170; VS-02260; DB-042758; N1795; Olean-12-en-29-oic acid, (3.beta.,20.beta.)-; 3.beta.-Hydroxy-11-oxo-18.alpha.-olean-12-en-30-oic acid; Olean-12-en-29-oic acid, (3.beta.,18.alpha.,20.beta.)-; (3.beta.,20.beta.)-3-Hydroxy-11-oxoolean-12-en-29-oic acid; 18.alpha.-olean-12-en-30-oic acid, 3.beta.-hydroxy-11-oxo-; 3-Hydroxy-11-oxoolean-12-en-29-oic acid, (3.beta.,20.beta.)- #; WLN: L F6 E6 B666 CV DUTJ A1 HVQ H1 K1 N1 O1 S1 S1 TQ -.alpha.; WLN: L F6 E6 B666 CV DUTJ A1 HVQ H1 K1 N1 O1 S1 S1 TQ -BETA; 10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid; 1970133-69-7; enoxolone; Glycyrrhetin; Uralenic acid; Arthrodont; Glycyrrhetinate; Spectrum_000254; SpecPlus_000869; Spectrum2_000464; Spectrum3_001216; Spectrum4_001890; Spectrum5_000520; BSPBio_002632; KBioGR_002424; KBioSS_000734; (18beta-glycyrrhetinic acid); DivK1c_000888; DivK1c_006965; SPECTRUM1500990; SPBio_000568; CHEMBL109757; Glycyrrhetinic acid - Enoxolone; SCHEMBL12807463; HMS502M10; KBio1_000888; KBio1_001909; KBio2_000734; KBio2_003302; KBio2_005870; KBio3_002132; NINDS_000888; HMS1921O08; Pharmakon1600-01500990; CCG-38703; NSC757815; NSC-757815; SDCCGMLS-0066713.P001; IDI1_000888; NCGC00178566-01; SBI-0051925.P002; AB00052447_03; BRD-A20200672-001-02-2; enoxolone; Glycyrrhetic acid; 18b-Glycyrrhetic acid; CHEMBL208873; 18b-Glycyrrhetinic acid; Glycyrrhetinic Acid, 8; 18 |A-Glycyrrhetintic Acid; SCHEMBL231125; BDBM23195; pentacyclic triterpene compound 8; 18 | cent-GLYCYRRHETINTIC ACID; AS-11631; SC-17800; Olean-12-en-29-oic acid, 3-hydroxy-11-oxo-, (3b,20b)-; (2S,4aS,6aS,6bR,10S,12aS,12bR,14bR)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-2-carboxylic acid; 18a-Glycyrrhetic acid; 18alpha-Glycyrrhetic acid; 1449-05-4; Glycyrrhetic acid; 18a-glycyrrhetinic acid; enoxolone; CHEMBL378653; GLYCYRRHETINIC ACID; 18ss -Glycyrrhetinic acid; SCHEMBL18539; BDBM50185128; AKOS016009638; DS-5150; 3A-Hydroxy-11-oxo-18ss20ss -olean-12-en-29-oic acid; Olean-12-en-29-oic acid, 3-hydroxy-11-oxo-, (3beta,18alpha,20beta)-; enoxolone; GLYCYRRHETINIC ACID; Glycyrrhetin; Biosone; Uralenic acid; Glycyrrhetic acid; Glycyrrhetinate; 3-Glycyrrhetinic acid; 18b-Glycyrrhetic acid; 18b-Glycyrrhetinic acid; Glycyrrhetinic; b-glycyrrhetic acid; a-glycyrrhetinic acid; beta-Glycyrrhetic acid; 18b-Glycyrrhtinic acid; SCHEMBL13144257; 3-hydroxy-11-oxoolean-12-en-29-oate; NCGC00186652-01; 3b-Hydroxy-11-oxoolean-12-en-30-oate; 3b-hydroxy-11-oxo-Olean-12-en-30-oate; 3b-Hydroxy-11-oxoolean-12-en-30-oic acid; 3b-hydroxy-11-oxo-Olean-12-en-30-oic acid; 3-hydroxy-11-oxoolean-12-en-29-oic acid (ACD/Name 4.0); (2S,4aS,6aS,6bR,10S,12aS)-10-hydroxy-2,4a,6a,6b,9,9,12a-heptamethyl-13-oxo-3,4,5,6,6a,7,8,8a,10,11,12,14b-dodecahydro-1H-picene-2-carboxylic acid; enoxolone; HMS3655J22; ZINC3977871; SW219582-1; Glycyrrhetic acid; 4-10-00-03775 (Beilstein Handbook Reference)
Enrofloxacin 1-Cyclopropyl-7-(4-ethyl-1-piperazinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid; Enrofloxacin; BAY VP 2674
Eosin 2',4',5',7'-Tetrabromo-3',6'-dihydroxyspiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, Disodium salt; Acid Red 87; C.I. 45380
Ephedrine alpha-[(1S)-[1-(methylamino)ethyl]benzenemethanol; Ephedrine; AI3-02761
Epinastine 9,13b-Dihydro-1H-dibenz[c,f]imidazo[1,5-a]azepin-3-amine; Epinastine; Epinastina [Spanish]
Epinephrine 4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; epinephrine; adrenaline; l-Adrenaline; L-epinephrine; 51-43-4; Adrenalin; Levoepinephrine; Adnephrine; Chelafrin; Epinefrina; Epinephran; Epirenan; (-)-Adrenaline; Nephridine; Adrenal; Epifrin; Renoform; Epipen; Vasoconstrictine; Hypernephrin; Renostypticin; Supracapsulin; Supranephrane; Suprarenaline; Adrenine; Hemisine; Hemostasin; Hemostatin; Levorenin; Levorenine; Lyophrin; Mucidrina; Nieraline; Paranephrin; Renaglandin; Renaleptine; Renalina; Scurenaline; Simplene; Styptirenal; Takamina; Vasotonin; Bosmin; Exadrin; (R)-Adrenaline; Adrin; l-Epirenamine; Bronkaid Mist; Primatene Mist; Sus-Phrine; Antiasthmatique; Esphygmogenina; Methylarterenol; Supranephrine; Adrenamine; Adrenapax; Adrenasol; Adrenodis; Adrenohorma; Adrenosan; Adrenutol; Astmahalin; Astminhal; Balmadren; Bernarenin; Biorenine; Brevirenin; Bronkaid; Drenamist; Dylephrin; Glaucosan; Glycirenan; Haemostasin; Haemostatin; Hektalin; Hyporenin; Intranefrin; Isoptoepinal; Kidoline; Myosthenine; Sindrenina; Soladren; Sphygmogenin; Stryptirenal; Supradin; Supranefran; Supranol; Takamine; Tokamina; Twinject; Vasodrine; Corisol; Glaucon; Mytrate; Suprel; Tonogen; Asthma-nefrin; Asmatane Mist; L(-)-Epinephrine; Sympathin I; (-)-(R)-Epinephrine; (R)-Epinephrine; Asthma meter mist; (-)-Epinephrine; Adrenalinum; Epiglaufrin; Glauposine; Adrenalin-Medihaler; Levorenen; Dyspne-Inhal; R-(-)-Epinephrine; Adrenalin in Oil; 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol; Epinefrin [Czech]; Epinefrin; Renostyptin; Surrenine; Citanest Forte; 1-Epinephrine; 1-Adrenalin; Epipen Jr.; Vaponefrin; (R)-(-)-Adrenaline; Rcra waste number P042; l-Epinephrine (synthetic); Adrenalina [DCIT]; Adrenatrate; Epinefrina [INN-Spanish]; Epinephrinum; Epinephrinum [INN-Latin]; Metanephrin; Micronefrin; Renaglandulin; Renostypricin; Epirenin; Renagladin; Surenine; Vasoton; l-Adrenalin; R-Adrenaline; Suprarenin; Eppy; Methylaminoethanolcatechol; Auvi-q; (R)-(-)-Epinephrine; l-Methylaminoethanolcatechol; d-Adrenaline; Medihaler-Epi; Vasoconstrictor; C9H13NO3; Lyodrin; Exadri; EPIPEN E Z PEN; (R)-(-)-Adnephrine; L-Epinehphrine; (R)-(-)-Epirenamine; l-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol; EPI E Z PEN JR; (-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol; RCRA waste no. P042; UNII-YKH834O4BH; Adrenalin (TN); Epirenamine; Levo-Methylaminoethanolcatechol; 4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; Epinephrine [USAN:INN:JAN]; SUS-PHRINE SULFITE-FREE; CCRIS 4812; (-)-R-Epinephrine; 1,2-Benzenediol, 4-(1-hydroxy-2-(methylamino)ethyl)-, (R)-; 4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol; AI3-19015; EPIPEN JR; HSDB 4289; EINECS 200-098-7; Lopac-E-4642; 1,2-Benzenediol, 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]-; NSC 62786; 1-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol; CHEMBL679; YKH834O4BH; Adrenan; Susphrine; Adrine; D-Epinephrine; (R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; Bupivacaine Hcl and Epinephrine; D-Epifrin; CHEBI:28918; UCTWMZQNUQWSLP-VIFPVBQESA-N; Benzyl alcohol, 3,4-dihydroxy-alpha-((methylamino)methyl)-, (-)-; Asthmanefrin; MFCD00002204; NCGC00015417-01; NCGC00142615-03; NCGC00142615-08; Adrenalina; 1,2-Benzenediol, 4-((1R)-1-hydroxy-2-(methylamino)ethyl)-; 1,2-Benzenediol, 4-(1-hydroxy-2-(methylamino)ethyl)-, (theta)-; DSSTox_CID_2986; Adrenaline (L-Adrenaline); DSSTox_RID_76819; L(-)-Epinephrine, 99%; DSSTox_GSID_22986; Epinephrin; Micronephrine; (-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol; (r)-4-(1-hydroxy-2-(methylamino)ethyl)benzene-1,2-diol; Adrenaclick; Racemic Epinephrine; 1,2-Benzenediol, 4-[1-hydroxy-2-(methylamino)ethyl]-, (R)-; l-Epinephine; Asthmahaler Mist; Ana-Guard; Ana-Kit; (+/-)-Epinephrine; CAS-51-43-4; Epipen EZ Pen; L-Adrenaline Base; Twinject 0.3; Epi EZ Pen Jr; ADROP; Epipen Auto-Injector; Twinject 0.15; Auvi-Q auto-injector; (+/-)-Adrenalin; Bronkaid Suspension Mist; 4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol; Epipen Jr. Auto-Injector; Levoreninum; Primatene; Symjepi; NSC62786; MFCD00063027; NSC-62786; Epinephrine [USP:INN:BAN:JAN]; ALE; IOP; (-)-Adrenalin; Epinephrine (USP); Epipen (TN); nchembio747-comp9; Twinject 0.30; Adrenaline/Epinephrine; Adrenaline (JP15); Adrenaline (JP17); Epitrate (Salt/Mix); Auvi-q (TN); Epinephrine (USP/INN); bmse000316; 4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol #; Citanest Forte (Salt/Mix); L-Adrenaline (Epinephrine); SCHEMBL3814; 3,4-Dihydroxy-.alpha.-((methylamino)methyl)benzyl alcohol; 4-[(1R)-1-hydroxy-2-methylamino-ethyl]benzene-1,2-diol; GTPL479; BIDD:GT0119; E4250_SIGMA; DTXSID5022986; BDBM44818; cid_6852374; CTK4J3509; HY-B0447B; ZINC39089; component of E-Pilo (Salt/Mix); (R)-(-)-3,4-Dihydroxy-alpha-(methylaminomethyl)benzyl alcohol; BCP09042; Tox21_111562; BDBM50029050; HSCI1_000215; LS-156; PDSP1_001120; PDSP2_001104; s2522; SBB012384; 51-43-4 (FREE BASE); AKOS024283500; Tox21_111562_1; CCG-204593; CS-2558; D29A657; DB00668; MCULE-9462717294; NE58416; SDCCGSBI-0050486.P002; SMP1_000227; (-)-Epinephrine, >=97.0% (NT); NCGC00142615-01; NCGC00142615-04; NCGC00142615-05; NCGC00142615-06; NCGC00142615-07; NCGC00142615-09; AC-13188; AS-13813; L926; ST069368; 4,5-beta-trihydroxy-N-methylphenethylamine; AB2000623; TR-033467; A0173; SW219274-1; 1401-EP2270011A1; 1401-EP2298735A1; 1401-EP2301934A1; 1401-EP2305677A1; 1401-EP2308562A2; 1401-EP2308861A1; 1401-EP2311464A1; 1401-EP2311823A1; 1401-EP2314571A2; 6367-EP2272841A1; 6367-EP2277861A1; 6367-EP2301934A1; 6367-EP2301936A1; 6367-EP2314571A2; C00788; D00095; J10365; 91382-EP2284149A1; 91382-EP2305636A1; AB00573227-11; AB00573227-12; AB00573227-13; AB00573227_14; AB00573227_15; 204017-EP2277867A2; 204017-EP2280003A2; Q132621; 4-(1-hydroxy-2-methylamino-ethyl)benzene-1,2-diol; Q-200601; SR-01000075267-8; 3,4-Dihydroxy-alpha-(methylaminomethyl)benzyl alcohol; 4-[(1R)-1-hydroxy-2-methylaminoethyl]benzene-1,2-diol; Z2686405805; (-)-3,4-dihydroxy-a-[(methylamino)methyl]-Benzyl alcohol; Adrenaline, European Pharmacopoeia (EP) Reference Standard; UNII-GR0L9S3J0F component UCTWMZQNUQWSLP-VIFPVBQESA-N; (+/-)-3,4-Dihydroxy-alpha-(methylaminomethyl)benzyl alcohol; (-)-3,4-dihydroxy-alpha-[(methylamino)methyl]-Benzyl alcohol; (-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol; 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]pyrocatechol; tartaric acid; Adrenaline with impurity F, European Pharmacopoeia (EP) Reference Standard; Benzyl alcohol, 3,4-dihydroxy-.alpha.-[(methylamino)methyl]-, (-)-; EPINEPHRINE (SEE ALSO: EPINEPHRINE HYDROCHLORIDE (CAS 55-31-2)); 2,3-dihydroxybutanedioic acid; 4-[(1R)-1-hydroxy-2-(methylamino)ethyl]benzene-1,2-diol; 2,3-bis(oxidanyl)butanedioic acid; 4-[(1R)-2-(methylamino)-1-oxidanyl-ethyl]benzene-1,2-diol; 51028-73-0; l-adrenaline,(-)adrenaline,l-epinephrine,l-3,4-dihydroxy-alpha-(methylaminomethyl)benzyl alcohol,l-1-methyl aminoethanol catechol; Epinephrine; Adnephrine
Equol (3S)-3,4-Dihydro-3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol; Equol; 531-95-3; (S)-3-(4-Hydroxyphenyl)chroman-7-ol; (S)-Equol; (-)-(S)-Equol; (-)-Equol; S-Equol; 4',7-Isoflavandiol; UNII-2T6D2HPX7Q; (S)-3,4-Dihydro-3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol; CCRIS 9222; EINECS 208-522-2; 2H-1-Benzopyran-7-ol, 3,4-dihydro-3-(4-hydroxyphenyl)-, (3S)-; 2T6D2HPX7Q; 4',7-Dihydroxyisoflavan; CHEMBL198877; (3S)-3-(4-hydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-7-ol; CHEBI:34741; AUS-131; (S)-(-)-4',7-Isoflavandiol; (3S)-3-(4-hydroxyphenyl)chroman-7-ol; 7,4'-dihydroxyisoflavan; 3,4-Dihydro-3-(4-hydroxyphenyl)-(S)-2H-1-benzopyran-7-ol; 7,4'-Isoflavandiol; AK-72897; 4',7-dihydroxy-3,4-dihydroisoflavone; 7-hydroxy-3-(4'-hydroxyphenyl)chroman; (3S)-Equol; SE 5OH; SCHEMBL43647; BIDD:ER0148; DTXSID0022309; AOB5550; AUS 131; ADFCQWZHKCXPAJ-GFCCVEGCSA-N; S-Equol, >=97% (HPLC); ZINC388661; (3S)-3,4-Dihydro-3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol; 66036-38-2; ACT03253; BCP13598; EX-A1354; 2127AH; BDBM50410528; s2450; AKOS016842347; ACN-001462; CS-7937; DB11674; MCULE-5874318771; SB17491; (3s)-3-(4-hydroxyphenyl)-7-chromanol; NCGC00386208-01; AS-71147; BR-72897; LS-39394; SC-19277; AX8015938; HY-100583; FT-0649148; ST24026586; SW219593-1; C14131; S-2179; 531D953; Q5384747; UNII-2RZ8A7D0E8 component ADFCQWZHKCXPAJ-GFCCVEGCSA-N; 3,4-dihydro-3-(4- hydroxyphenyl)-(S)-2H-1-benzopyran-7-ol; Equol; EINECS 208-522-2
Ergosterol (3beta,22E)-Ergosta-5,7,22-trien-3-ol; Ergosterin; ergosta-5,7,22-trien-3-ol; Provitamine D2; 24-Methylcholesta-5,7,22-trien-3beta-ol; 24a-Methyl-22E-dehydrocholesterol; 24alpha-Methyl-22E-dehydrocholestero; (24R)-Ergosta-5,7,22-trien-3b-ol; (3beta)-Ergosta-5,7,22-trien-3-ol; 24-Methylcholesta-5,7,22-trien-3b-ol; 24R-Methylcholesta-5,7,22E-trien-3b-ol; (3beta,2E)-Ergosta-5,7,22-trien-3-ol; (3beta,22E)-Ergosta-5,7,22-trien-3-ol; 24R-Methylcholesta-5,7,22E-trien-3beta-ol; A831651; (3S,10R,13R)-17-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,9,11,12,14,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-3-ol; Ergosterol; AI3-18876
Erythritol (2R,3S)-rel-1,2,3,4-Butanetetrol; Erythritol; Antierythrite
Erythromycin erythromycin; Erythromycin A; 114-07-8; E-Mycin; Abomacetin; Erythrocin; Erythromycinum; Erymax; Emgel; Eritromicina; Erythromycine; Erythro-Statin; Ilotycin; E-Glades; Eryacne; (-)-ERYTHROMYCIN; Erythromycin base; Torlamicina; Abboticin; Erycette; Robimycin; Ery-Tab; E-Base; erythro; Erythroguent; Dumotrycin; Eritrocina; Erycinum; Erythrogran; Erythromid; Mephamycin; Pantomicina; Propiocine; Stiemycin; Dotycin; Ermycin; Erycen; Erycin; Eryderm; Erygel; Ilocaps; Sansac; Aknin; Wemid; ERYC; Eryc Sprinkles; Erythra-Derm; Theramycin Z; Kesso-Mycin; Akne-Mycin; Taimoxin-F; Ak-Mycin; Erythromast 36; Erythromycin Lactate; T-Stat; R-P Mycin; Benzamycin; Endoeritrin; Eritomicina; Erythroderm; Erytrociclin; Paediathrocin; Pharyngocin; Proterytrin; Acneryne; Acnesol; Aknemycin; Derimer; Deripil; Erisone; Eryacnen; Erydermer; Eryhexal; Erysafe; Iloticina; Latotryd; Lederpax; Mercina; Oftamolets; Pantoderm; Pantodrin; Primacine; Romycin; Stiemicyn; Tiloryth; Tiprocin; E-Solve 2; Emuvin; Emycin; Erecin; Erymed; Erytab; Erytop; Inderm; Retcin; AustriaS; Eros; Ery-maxin; Erythro-Teva; Sans-acne; Erimycin-T; Ery-Diolan; Inderm Gel; Del-Mycin; UNII-63937KV33D; Aknederm Ery Gel; Udima Ery Gel; Eryc 125; Emu-Ve; Skid Gel E; Akne Cordes Losung; Ilosone (estolate); E-Mycin (base); Ery-Tab (base); E-Base (base); Emu-V; Ery-B; CHEMBL532; ERYC (base); C-Solve-2; PCE Dispertab (base); erythromycin-A; Eryc-125; Eryc-250; CHEBI:42355; ULGZDMOVFRHVEP-RWJQBGPGSA-N; Eritromicina [INN-Spanish]; Erythromycine [INN-French]; Erythromycinum [INN-Latin]; A/T/S; Oftalmolosa Cusi Eritromicina; 63937KV33D; NCI-C55674; MFCD00084654; DSSTox_CID_2991; (-)-Erythromycin, 98%; UNII-8HPH7ND0LN; DSSTox_RID_76820; DSSTox_GSID_22991; 8HPH7ND0LN; (3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-((2,6-Dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl)oxy)-14-ethyl-7,12,13-trihydroxy-3,5,7,9,11,13-hexamethyl-6-((3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl)oxy)oxacyclotetradecane-2,10-dione; ERY; Ilotycin T.S.; (-)-Erythromycin, Eur.Ph.; CCRIS 9078; HSDB 3074; N-Methylerythromycin A; EINECS 204-040-1; NSC 55929; Staticin (TN); Akne-mycin (TN); AI3-50138; Erygel (TN); Eryc (TN); T-stat (TN); Pce (TN); SR-05000001618; Sentry AQ mardel maracyn; erthromycin; Erythromycines; ULGZDMOVFRHVEP-UHFFFAOYSA-N; NSC55929; NSC-55929; NCGC00094670-01; Erythromycin [USP:INN:BAN:JAN]; 82343-12-2; CAS-114-07-8; Prestwick_205; Erythromycin C-13; Spectrum_000115; Spectrum_000659; EM-A; Prestwick3_000151; Spectrum2_000759; Spectrum2_001263; Spectrum4_000538; Spectrum5_001596; E0751; Erythromycin A, B + C; EC 204-040-1; SCHEMBL2601; BSPBio_000282; BSPBio_002480; KBioGR_001175; KBioSS_000555; KBioSS_001139; MLS001066618; BIDD:GT0017; DivK1c_000294; DivK1c_000397; DivK1c_000702; SPECTRUM1500280; SPBio_000778; SPBio_001226; BPBio1_000312; GTPL1456; DTXSID4022991; Erythromycin (JP17/USP/INN); HMS500O16; KBio1_000294; KBio1_000397; KBio1_000702; KBio2_000555; KBio2_001139; KBio2_003123; KBio2_003707; KBio2_005691; KBio2_006275; J01FA01; Erythromycin (mixture of A,B,C); NINDS_000294; NINDS_000397; NINDS_000702; ZX-AFC000696; HMS1920M04; HMS2091D05; HMS2095O04; HMS3712O04; Pharmakon1600-01500280; ACT03320; HY-B0220; RKL10096; Tox21_111311; Tox21_111869; Tox21_300515; BDBM50344942; CCG-38992; LMPK04000006; NSC756759; ZINC85534336; Erythromycin, labeled with carbon-13; AKOS015895249; CS-2168; DB00199; MCULE-4566208867; NSC-756759; IDI1_000294; IDI1_000397; IDI1_000702; SMP1_000119; NCGC00179619-01; NCGC00179619-02; NCGC00179619-03; NCGC00254234-01; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione; AC-12744; AC-12901; CC-27517; CPD000544946; SAM002643510; SC-13736; SMR000544946; Erythromycin, potency: >=850 mug per mg; Erythromycin, tested according to Ph.Eur.; SBI-0051368.P003; Erythromycin, N-demethyl-N-(methyl-11C)-; LS-187077; Erythromycin, meets USP testing specifications; C01912; D00140; E-3250; Erythromycin, plant cell culture tested, ~98%; 44496-EP2272846A1; 44496-EP2275422A1; 44496-EP2292608A1; 44496-EP2305644A1; 44496-EP2308866A1; 44496-EP2311814A1; 44496-EP2311828A1; 44496-EP2380568A1; AB00051981_09; AB00051981_10; Erythromycin standard solution, 1 mg/mL in H2O; Erythromycin, Biotechnology Performance Certified; 114E078; C-23475; Q213511; SR-01000799155; 9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione; Erythromycin, Antibiotic for Culture Media Use Only; Erythromycin, BioReagent, suitable for cell culture; SR-01000799155-2; SR-05000001618-1; SR-05000001618-2; BRD-K63550407-001-13-5; BRD-K63550407-028-03-9; Erythromycin A, British Pharmacopoeia (BP) Reference Standard; Erythromycin A, European Pharmacopoeia (EP) Reference Standard; Erythromycin, United States Pharmacopeia (USP) Reference Standard; Erythromycin, for microbiological assay, European Pharmacopoeia (EP) Reference Standard; Erythromycin, Pharmaceutical Secondary Standard; Certified Reference Material; (2R,3S,4S,5R,6R,8R,10R,11R,12S,13R)-5-(3-amino-3,4,6-trideoxy-N,N-dimethyl--D-xylo-hexopyranosyloxy)-3-(2,6-dideoxy-3-C,3-O-dimethyl--L-ribo-hexopyranosyloxy)-13-ethyl-6,11,12-trihydroxy-2,4,6,8,10,12-hexamethyl-9-oxotridecan-13-olide; (3R*,4S*,5S*,6R*,7R*,9R*,11R*,12R*,13S*,14R*)-4-[(2,6-Dideoxy-3-C-methyl-3-O-methyl-.alpha.-L-ribo-hexopyranosyl)oxy]-14-ethyl-7,12,13-trihydroxy-3,5,9,11,13-hexamethyl-6-[[3,4,6-trideoxy-3-; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-(2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyloxy)-14-ethyl-7,12,13-trihydroxy-6-[3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyloxy]-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-(((2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-14-ethyl-7,12,13-trihydroxy-4-(((2R,4R,5S,6S)-5-hydroxy-4-methoxy-4; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione; (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyltetrahydro-2H-pyran-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyltetrahydro-2H-pyran-2-yl]oxy}-3,5,7,9,11,13-hexamethyloxacyclotetradecane-2,10-dione (non-preferred name); (3R,4S,5S,6R,7S,9R,11R,12R,13R,14R)-6-{[(2S,3R,4S,6R)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy}-14-ethyl-7,12,13-trihydroxy-4-{[(2R,4S,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy}-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione; 215031-94-0; Abboticin
Esculin 6-(beta-D-Glucopyranosyloxy)-7-hydroxy-2H-1-benzopyran-2-one; Esculin; aesculin; 531-75-9; Esculoside; (-)-Esculin; Polychrome; Esculin hydrate; 6,7-Dihydroxycoumarin-6-O-glucoside; Esculine; Esculetin 6-O-glucoside; 6,7-Dihydroxycoumarin 6-glucoside; UNII-1Y1L18LQAF; Esculetin 6-beta-D-glucoside; 6-(beta-D-Glucopyranosyloxy)-7-hydroxy-cumarin; 7-Hydroxy-6-cumarinyl-glucosid; 6-(beta-D-Glucopyranosyloxy)-7-hydroxy-2H-1-benzopyran-2-one; 1Y1L18LQAF; CHEBI:4853; XHCADAYNFIFUHF-TVKJYDDYSA-N; Aesculetin glukosid; 7-Hydroxy-6-glucosyloxy-2H-chromene; Esculin hydrate, 97%; Venoplant; Esculin sesquihydrate; MFCD00149492; Enallachrome; Bicolorin; Crataegin; Escosyl; 7-hydroxy-6-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-2H-chromen-2-one; CCRIS 5724; 7-hydroxy-2-oxo-2H-chromen-6-yl beta-D-glucopyranoside; Vitamin C2; EINECS 208-517-5; 7-Hydroxy-6-glucosyloxy-2H-chromen; NSC 26665; 66778-17-4; Aesculinum; 2H-1-Benzopyran-2-one, 6-(beta-D-glucopyranosyloxy)-7-hydroxy-; SR-01000633930; NSC-26665; esculetin glukosid; NCGC00016491-01; CAS-531-75-9; Aesculin (Esculin); Aesculin sesquihydrate; Spectrum_000361; Spectrum2_000576; Spectrum3_000731; Spectrum4_001923; Spectrum5_000845; SCHEMBL2893; DSSTox_CID_25318; DSSTox_RID_80798; DSSTox_GSID_45318; BSPBio_002282; KBioGR_002266; KBioSS_000841; DivK1c_000956; SPECTRUM1500901; SPBio_000392; CHEMBL482581; DTXSID7045318; Esculetin-6-b-D-glucopyranoside; BCBcMAP01_000202; Esculetin 6-.beta.-D-glucoside; HMS502P18; KBio1_000956; KBio2_000841; KBio2_003409; KBio2_005977; KBio3_001502; BIE3461; NINDS_000956; HMS1921M16; 6,7-Dihydroxycoumarin-6-glucoside; Esculetin-6-beta-D-glucopyranoside; HY-N0188; ZINC3860441; Tox21_110453; CCG-38501; GC4131; s2258; AKOS015895151; DB13155; EBD2138591; MCULE-8058387809; SDCCGMLS-0066653.P001; IDI1_000956; SMP1_000008; 6,7-Dihydroxycoumarine-6-glucopyranoside; SC-15781; CS-0007892; E0024; FT-0603455; N1766; 7-Hydroxycoumarin-6-yl beta-D-Glucopyranoside; C09264; 6-(.beta.-D-Glucopyranosyloxy)-7-hydroxy-cumarin; Q376432; 6,7-dihydroxycoumarin 6-(beta-D-glucopyranoside); SR-01000633930-1; SR-01000633930-3; BRD-K51742987-001-02-3; BRD-K51742987-002-02-1; Esculin, European Pharmacopoeia (EP) Reference Standard; 6-(.beta.-D-Glucopyranosyloxy)-7-hydroxy-2H-1-benzopyran-2-one; 7-hydroxy-6-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-2H-chromen-2-one; 2H-1-Benzopyran-2-one, 6-(beta-D-glucopyranosyloxy)-7-hydroxy-; CCRIS 5724
Estazolam estazolam; 29975-16-4; Eurodin; ProSom; Nuctalon; Julodin; Esilgan; D 40TA; Estazolamum; 8-Chloro-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; D-40TA; Abbott 47631; Estazolamum [INN-Latin]; Estazolam [USAN:INN:JAN]; Abbott-47631; 8-Chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine; UNII-36S3EQV54C; NSC 290818; CCRIS 1955; U 33737; EINECS 249-982-4; BRN 1220868; 36S3EQV54C; CHEBI:4858; DEA No. 2756; CDCHDCWJMGXXRH-UHFFFAOYSA-N; 8-Chloro-6-phenyl-4H-(1,2,4)triazolo-(4,3-a)(1,4)benzodiazepine; 8-Chloro-6-phenyl-4H-s-triazolo(4,3-a)(1,4)benzodiazepine (IUPAC); NSC-290818; NCGC00168250-01; 8-Chloro-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine; Nemurel; Somnatrol; Cannoc; 4H-s-Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-phenyl-; 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-phenyl-; 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-6-phenyl-; C16H11ClN4; 53180-72-6; Q-201071; D40TA; Prosom (TN); Estazolam civ; 8-Chloro-6-phenyl-4H-(1,2,4)triazolo(4,3-a)(1,4)benzodiazepine; Eurodin|||ProSom; DSSTox_CID_572; DSSTox_RID_75665; DSSTox_GSID_20572; SCHEMBL28766; MLS003899222; BIDD:GT0481; CHEMBL285674; GTPL7550; ZINC1370; Estazolam (JP17/USAN/INN); DTXSID5020572; CDCHDCWJMGXXRH-UHFFFAOYSA-; Estazolam 0.1 mg/ml in Methanol; Estazolam 1.0 mg/ml in Methanol; BCP13317; Tox21_112609; 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-6-phenyl; 8-chloro-6-phenyl-4H-s-triazolo[4,3-(alpha)] [1,4]benzodiazepine; MFCD00867537; NSC290818; AKOS005064373; AB07556; DB01215; LS-7378; CC-27529; SMR000238168; CAS-29975-16-4; FT-0630552; WLN: T B576 BN DNN HN GHJ IR& LG; C06981; D00311; 975E164; A820132; C-18475; Q3045264; 8-Chloro-6-phenyl-4H-s-triazolo[4,4]benzodiazepine; 4H-s-Triazolo[4,4]benzodiazepine, 8-chloro-6-phenyl-; Estazolam solution, drug standard, 100 mug/L in methanol; 8-chloro-6-phenyl-4H-s-triazolo [4,3-a][1,4] benzodiazepine; 8-chloro-6-phenyl-4H-s-triazolo-[4,3-a][1,4]benzodiazepine; Estazolam, United States Pharmacopeia (USP) Reference Standard; 4H-[1,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-6-phenyl-; 8-Chloro-6-phenyl-4H-[1,4]triazolo[4,3-a][1,4]benzodiazepine; 8-chloranyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine; Estazolam solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; 12-chloro-9-phenyl-2,4,5,8-tetraazatricyclo[8.4.0.0^{2,6}]tetradeca-1(10),3,5,8,11,13-hexaene; InChI=1/C16H11ClN4/c17-12-6-7-14-13(8-12)16(11-4-2-1-3-5-11)18-9-15-20-19-10-21(14)15/h1-8,10H,9H2; D-40TA
Estradiol (17beta)Estra-1,3,5(10)triene-3,17-diol; Estradiol; Altrad
Estriol (16 alpha, 17 beta)-Estra-1,3,5(10)-triene-3,16,17-triol; Estriol; A 13610
Estrone 3-Hydroxyestra-1,3,5(10)trien-17-one; Estrone; 3-08-00-01171 (Beilstein Handbook Reference)
Estrone sulphate 3-(Sulfooxy)-estra-1,3,5(10)-trien-17-one; Estrone sulfate; EINECS 207-575-9
Ethacridine lactate 2-Hydroxypropanoic acid compd. with 7-ethoxy-3,9-acridineamine (1:1); Acrinol; Acridine, 6,9-diamino-2-ethoxy-, compd. with lactic acid (1:1)
Ethacrynic acid 2-[2,3-Dichloro-4-(2-methylene-1-oxobutyl)phenoxy]acetic acid; Ethacrynic acid; Acetic acid, (2,3-dichloro-4-(2-methylenebutyryl)phenoxy)-
Ethane sulphonate Ethanesulfonic acid; Ethane sulfonate; EINECS 209-843-0
Ethinyl estradiol (17alpha)-19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol; ethinyl estradiol; Ethynylestradiol; Ethynyl estradiol; ETHINYLESTRADIOL; 57-63-6; Ethinyloestradiol; Ginestrene; 17-Ethinylestradiol; Progynon C; Ethinoral; Eticyclin; Eticyclol; Etinestrol; Etinestryl; Etinoestryl; Etistradiol; Follicoral; Novestrol; Orestralyn; Spanestrin; Amenoron; Dyloform; Ertonyl; Estigyn; Estinyl; Estoral; Estorals; Ethidol; Inestra; Linoral; Lynoral; Menolyn; Oradiol; Primogyn; Esteed; 17alpha-Ethynylestradiol; Neo-Estrone; Primogyn C; Primogyn M; Nogest-S; Eston-E; Feminone; Palonyl; Perovex; 17-Ethynylestradiol; Diogyn E; Microfollin; Chee-O-Genf; Chee-O-Gen; 17-Ethinyl-3,17-estradiol; Ethynyloestradiol; 17-Ethinyl-3,17-oestradiol; 17-Ethynyloestradiol; Estoral (Orion); 17alpha-Ethinyl estradiol; Amenorone; Diprol; 17alpha-Ethinylestradiol; Ethinyl-oestranol; Diognat-E; Diogyn-E; Aethinyloestradiolum; Ethinylestriol; Estopherol; Eticylol; Kolpolyn; Orestrayln; Ylestrol; Anovlar; Etivex; Progynon M; Ethinyl E2; Estradiol, 17-ethynyl-; Estoral (VAN); Aethinyoestradiol [German]; 17a-Ethynylestradiol; Etinilestradiol [INN-Spanish]; EE(sub 2); NSC-10973; Etinilestradiolo [DCIT]; 17alpha-Ethynyloestradiol; Ethinylestradiolum [INN-Latin]; 17-alpha-Ethynylestradiol; Ethinyl Estradiol [USP]; 17alpha-Ethinylestradiol-17beta; Ethinylestradiol [INN:BAN:JAN]; ethynyl-estradiol; 17-alpha-Ethynylestradiol-17-beta; 17.alpha.-Ethinylestradiol; 17.alpha.-Ethynylestradiol; Estoral [Orion]; 17-alpha-Ethinyl-17-beta-estradiol; 17.alpha.-Ethynyloestradiol; 17-alpha-Ethynyl-17-beta-oestradiol; CCRIS 286; 17a-Ethinylestradiol; UNII-423D2T571U; HSDB 3587; 17 alpha-ethinyestradiol; Ethinyl estradiol (USP); EINECS 200-342-2; EE; CHEMBL691; OVULEN-21; OVULEN-28; 17-alpha-ethynyl estradiol; 17.alpha.-Ethinyl-17.beta.-estradiol; BRN 2419975; Ethinyloestradiol [Steroidal oestrogens]; 17.alpha.-Ethynyl-17.beta.-oestradiol; Norinyl; AI3-52941; MLS000028479; CHEBI:4903; EE2; EO; Prosexol; BFPYWIDHMRZLRN-SLHNCBLASA-N; 17-Ethynyl-3,17-dihydroxy-1,3,5-oestratriene; 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17alpha)-; 17.alpha.-Ethynylestradiol-l7.beta.; 17-alpha-Ethynyl-1,3,5-oestratriene-3,17-beta-diol; 423D2T571U; (8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; 17.alpha.-Ethynyloestradiol-17.beta.; 17alpha-ethinylestra-1,3,5(10)-triene-3,17beta-diol; 17alpha-ethinyloestra-1,3,5(10)-triene-3,17beta-diol; 17-alpha-Ethinylestra-1,3,5(10)-triene-3,17-beta-diol; 17-alpha-Ethynyl-1,3,5(10)-estratriene-3,17-beta-diol; NCGC00091533-04; Etinilestradiol; 17-alpha-Ethinyloestra-1,3,5(10)-triene-3,17-beta-diol; 17-alpha-Ethynyl-1,3,5(10)-oestratriene-3,17-beta-diol; 17alpha-Ethinyl-3,17-dihydroxy-delta(sup1,3,5)-estratriene; 17alpha-ethinyl-3,17-dihydroxy-delta(sup1,3,5)oestratriene; 3,17beta-Dihydroxy-17alpha-ethynyl-1,3,5(10)-estratriene; 3,17beta-Dihydroxy-17alpha-ethynyl-1,3,5(10)-oestratriene; Certostat; Estra-1,3,5(10)-triene-3,17beta-diol, 17alpha-ethynyl-; Ethinylestradiol, 98%; SMR000058319; 17-alpha-Ethinyl-3,17-dihydroxy-delta(sup 1,3,5)-estratriene; 19-Nor-17alpha-pregna-1,3,5(10)-trien-20-yne-3,17-diol; 3,17-beta-Dihydroxy-17-alpha-ethynyl-1,3,5(10)-estratriene; 3,17-beta-Dihydroxy-17-alpha-ethynyl-1,3,5(10)-oestratriene; Estra-1,3,5(10)-triene-3,17-beta-diol, 17-alpha-ethynyl-; Etinilestradiolo; (17-alpha)-19-Norpregna-1,3,5(10)-trien-20-yne-3,17,diol; 17alpha-ethinyl-delta(sup1,3,5(10))oestratriene-3,17-beta -diol; 17alpha-Ethynyloestradiol-17beta; 17beta-Estradiol, 17-ethynyl-; 19-Nor-17-alpha-pregna-1,3,5(10)-triene-20-yne-3,17-diol; DSSTox_CID_576; Aethinyoestradiol; 17-alpha-Ethinyl-delta(sup 1,3,5(10))oestratriene-3,17-beta-diol; Ethinylestradiolum; Microfollin Forte; DSSTox_RID_75668; DSSTox_GSID_20576; 17alpha-Ethynylestra-1,3,5(10)-triene-3,17beta-diol; (17beta)-17-ethynylestra-1(10),2,4-triene-3,17-diol; 17alpha-ethinyl-estra-1,3,5(10)-triene-3,17beta-diol; (17alpha)-19-norpregna-1,3,5(10)-trien-20-yne-3,17-diol; 19-Nor-17-alpha-pregna-1,3,5(10)-trien-20-yne-3,17-diol; CAS-57-63-6; (1S,10R,11S,14R,15S)-14-ethynyl-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2(7),3,5-triene-5,14-diol; (8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; component of Oracon; component of Ortrel; Estinyl (TN); component of Demulen; Estra-1,5(10)-triene-3,17.beta.-diol, 17-ethynyl-; Estra-1,5[10]-triene-3,17.beta.-diol, 17-ethynyl-; Ylestol; 19-Nor-17.alpha.-pregna-1,5(10)-trien-20-yne-3,17-diol; 19-Nor-17.alpha.-pregna-1,5[10]-trien-20-yne-3,17-diol; 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17.alpha.)-; 17alpha-Ethinyl-17beta-estradiol; component of Ovral; 3WF; Levlen (Salt/Mix); MFCD00003690; Oracon (Salt/Mix); Ortrel (Salt/Mix); Anovlar (Salt/Mix); Desogen (Salt/Mix); 17a-Ethynyloestradiol; Estoral {[Orion]}; Nordette (Salt/Mix); PUBERTAL ETHINYL ESTRADIOL STUDY; Secrovin (Salt/Mix); Seasonale (Salt/Mix); Triphasil (Salt/Mix); Estopherol (Salt/Mix); Seasonique (Salt/Mix); 17-Ethynylestradiol ram; Ortho Evra (Salt/Mix); Tri-Levlen (Salt/Mix); Opera_ID_1808; 17 alpha Ethynylestradiol; 17a-Ethynylestradiol-l7b; 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol; Ortho-Cyclen (Salt/Mix); 17a-Ethynyloestradiol-17b; SCHEMBL4071; 17a-Ethinyl-17b-estradiol; 17a-Ethynyl-17b-oestradiol; MLS000758274; MLS001424011; BIDD:ER0162; Ethinylestradiol (JP17/INN); GTPL7071; SGCUT00127; DTXSID5020576; HMS2051I19; HMS2235J09; HMS3715J09; 17alpha-Ethynylestradiol, >=98%; 17.beta.-Estradiol, 17-ethynyl-; HY-B0216; NSC10973; to_000048; ZINC3812897; Tox21_111147; Tox21_201291; Tox21_300413; BDBM50187243; LMST02010036; LS-231; s1625; SBB066068; 17|A-Ethynylestradiol; Ethynylestradiol; AKOS015894925; Tox21_111147_1; AC-2169; CCG-100819; CS-2161; DB00977; KS-5257; MCULE-5991854877; NC00069; 17.alpha.-ethinyl-3,3,5)oestratriene; 17.alpha.-Ethinyl-3,3,5)-estratriene; NCGC00091533-01; NCGC00091533-05; NCGC00091533-07; NCGC00091533-08; NCGC00091533-09; NCGC00091533-10; NCGC00254514-01; NCGC00258843-01; NCI60_000234; ST081364; AB2000171; 392-EP2270017A1; 392-EP2272846A1; 392-EP2275422A1; 392-EP2277622A1; 392-EP2281816A1; 392-EP2308866A1; 392-EP2372017A1; 392-EP2374791A1; FT-0625736; 17-Ethynyl-3-17-dihydroxy-1,5-oestratriene; 17alpha-Ethynylestradiol, >=98.0% (HPLC); C07534; D00554; EN300-119516; 17-Ethynyl-3-17-dihydroxy-1,3,5-oestratriene; AB00441335-11; AB00441335_12; WLN: L E5 B666TTT&J E1 FQ F1UU1 OQ; 003E690; Q415563; SR-01000721903; 17-Ethynylestra-1,3,5(10)-triene-3,17beta-diol; 17a-Ethinylestradiol 100 microg/mL in Acetonitrile; Q-201076; SR-01000721903-3; 17-Ethynyloestra-1,5(10)-triene-3,17.beta.-diol; 17.alpha.-Ethynyl-1,5-estratriene-3,17.beta.-diol; 17.alpha.-Ethynyl-1,5-oestratriene-3,17.beta.-diol; 17a-Ethinylestradiol 100 microg/mL in Methanol/Water; 17alpha-Ethinyl-1,3,5(10)-estratriene-3,17-diol; BRD-K48195008-001-19-9; TRANSGENIC MODEL EVALUATION (ETHINYL ESTRADIOL); 17-Ethynyloestra-1,3,5(10)-triene-3,17.beta.-diol; 17.alpha.-Ethinyl-1,3,5(10)-estratriene-3,17-diol; 17alpha-Ethynyl-1,3,5(10)-estratriene-3,17beta-diol; Z1541638513; (17beta)-17-ethynylestra-1,3,5(10)-triene-3,17-diol; 17.alpha.-ethinylestra-1,5(10)-triene-3,17.beta.-diol; 17.alpha.-ethinyloestra-1,5(10)-triene-3,17.beta.-diol; 17.alpha.-Ethynylestra-1,5(10)-triene-3,17.beta.-diol; 17.alpha.-Ethynyloestra-1,5(10)-triene-3,17.beta.-diol; 17.alpha.-ethinylestra-1,3,5(10)-triene-3,17.beta.-diol; 17.alpha.-ethinyloestra-1,3,5(10)-triene-3,17.beta.-diol; 17.alpha.-Ethynyl-1,3,5(10)-estratriene-3,17.beta.-diol; 17.alpha.-Ethynyl-1,3,5(10)-oestratriene-3,17.beta.-diol; 17.alpha.-Ethynylestra-1,3,5(10)-triene-3,17.beta.-diol; 17.alpha.-Ethynyloestra-1,3,5(10)-triene-3,17.beta.-diol; 17alpha-Ethynylestradiol, VETRANAL(TM), analytical standard; 19-Nor-1,3,5(10),17alpha-pregnatrien-20-yne-3,17-diol; 19-nor-17.alpha.-Pregna-1,5(10)-trien-2-yne-3,17-diol; Estra-1,5(10)-triene-3,17.beta.-diol, 17.alpha.-ethynyl-; 17.alpha.-Ethinyl-3,17-dihydroxy-.delta.(sup1,3,5)-estratriene; 17.alpha.-ethinyl-3,17-dihydroxy-.delta.(sup1,3,5)oestratriene; 19-Nor-17.alpha.-pregna-1,3,5(10)-trien-20-yn-3,17-diol; 19-Nor-17.alpha.-pregna-1,3,5(10)-trien-20-yne-3,17-diol; 19-Norpregna-1,3,5(10)-trien-20-yne-3,17-diol, (17a)-; 19-Norpregna-1,5(10)-trien-20-yne-3,17-diol, (17.alpha.)-; 3,17.beta.-Dihydroxy-17.alpha.-ethynyl-1,3,5(10)-estratriene; 3,17.beta.-Dihydroxy-17.alpha.-ethynyl-1,3,5(10)-oestratriene; Estra-1,3,5(10)-triene-3,17.beta.-diol, 17.alpha.-ethynyl-; Ethinylestradiol, European Pharmacopoeia (EP) Reference Standard; 17.alpha.-ethinyl-.delta.(sup1,3,5(10))oestratriene-3,17-.beta. -diol; 17.alpha.-ethinyl-.delta.(sup1,5(10))oestratriene-3,17-.beta.-diol; 19-Nor-17.alpha.-pregna-1,3,5(10)-trien-20-yne-3,17.beta.-diol; Ethinyl estradiol, United States Pharmacopeia (USP) Reference Standard; (9beta,13alpha,14beta,17alpha)-17-ethynylestra-1(10),2,4-triene-3,17-diol; ENDOCRINE DISRUPTOR (ETHINYL ESTRADIOL) (SEE ALSO ETHINYL ESTRADIOL (57-63-6)); Ethinyl Estradiol, Pharmaceutical Secondary Standard; Certified Reference Material; Ethinylestradiol for system suitability, European Pharmacopoeia (EP) Reference Standard; (1S,11S,15S,10R,14R)-14-ethynyl-15-methyltetracyclo[8.7.0.0<2,7>.0<11,15>]hept adeca-2(7),3,5-triene-5,14-diol; (1S,11S,15S,10R,14R)-14-ethynyl-15-methyltetracyclo[8.7.0.0<2,7>.0<11,15>]hept adeca-2,4,6-triene-5,14-diol; Ethinylestradiol; 4-06-00-06877 (Beilstein Handbook Reference)
Ethionamide ethionamide; 536-33-4; 2-ethylpyridine-4-carbothioamide; Ethioniamide; Ethyonomide; Amidazine; Ethinamide; Etionamid; Etioniamid; Thioamide; Ethylisothiamide; Trecator; Trecator-SC; 2-Ethylthioisonicotinamide; Amidazin; Ethimide; Etiocidan; Etionizin; EtioniziEtionizine; Fatoliamid; Iridocin; Iridozin; Isotiamida; Itiocide; Nicotion; Rigenicid; Sertinon; Thianide; Thioniden; Trekator; Trescatyl; Trescazide; Tubenamide; Tubermin; Tuberoid; Tuberoson; AetiAetiva; EthiEtimid; Etionid; Isothin; Nizotin; Teberus; Thianid; Tianid; Ati4-Pyridinecarbothioamide, 2-ethyl-; Bayer 5312; Ethionamid prothionamid; Iridocin Bayer; Aethionamidum; Nisotin; Thiomid; Etionamide [DCIT]; Tio-Mid; 2-ETHYL-4-PYRIDINECARBOTHIOAMIDE; Ethionamidum; Etionamida; Etionamide; Tiomid; 2-Ethylisothionicotinamide; 2-Ethylisonicotinothioamide; Ethionamidum [INN-Latin]; Etionamida [INN-Spanish]; Ethina (VAN); 2-Ethyl-4-thiocarbamoylpyridine; 2-Ethyl-thioisonicotinamide; 1314 TH; 2-Ethylisonicotinic acid thioamide; TH 1314; 2-ethyl-4-thiopyridylamide; NCI-C01694; alpha-Ethylisothionicotinamide; alpha-Ethylthioisonicotinamide; alpha-Ethylisonicotinoylthioamide; UNII-OAY8ORS3CQ; 1314-Th; F.I. 58-30; 1314TH; alpha-Ethylisonicotinic acid thioamide; 2-Ethylisonicotinic thioamide; 2-Ethyl-4-thioamidylpyridine; CCRIS 287; Isonicotinamide, 2-ethylthio-; C8H10N2S; HSDB 7473; OAY8ORS3CQ; EINECS 208-628-9; ETP; NSC 255115; BRN 0116474; MLS000069764; CHEBI:4885; .alpha.-Ethylisothionicotinamide; .alpha.-Ethylthioisonicotinamide; AEOCXXJPGCBFJA-UHFFFAOYSA-N; .alpha.-Ethylisonicotinoylthioamide; Trecator SC; Isonicotinimidic acid, 2-ethylthio-; NSC255115; NSC-255115; 1314 TN; .alpha.-Ethylisonicotinic acid thioamide; NCGC00016497-05; AK163496; CAS-536-33-4; CPD001370750; SMR000058716; DSSTox_CID_577; DSSTox_RID_75669; DSSTox_GSID_20577; W-105719; Ethatyl; amino(2-ethyl(4-pyridyl))methane-1-thione; Trecator-SC (TN); Bayer5312; SR-01000759219; Ethionamide [USAN:INN:BAN:JAN]; 3-Ethylisothionicotinamide; 2-e thylisothionicotinamide; 2-Ethylisonicotinoylthioamide; Thiodine; alpha-ethylt hioisonicotinamide; 2-ethylisonicotinic acid thiomide; 2-ethyl-4-aminothiocarbonylpyridine; Prestwick_842; Ethionamide [USAN:USP:INN:BAN:JAN]; PubChem15920; Spectrum_001082; Opera_ID_632; Prestwick0_000526; Prestwick1_000526; Prestwick2_000526; Prestwick3_000526; Spectrum2_000994; Spectrum3_000428; Spectrum4_000547; Spectrum5_000979; 2-Ethylisonicotinothiamide; 2-Ethylisonicotinthioamide; E0695; CHEMBL1441; SCHEMBL27007; BSPBio_000511; BSPBio_002016; KBioGR_001213; KBioSS_001562; 5-22-02-00360 (Beilstein Handbook Reference); KSC492I0R; MLS001074114; MLS002454402; DivK1c_000145; SPECTRUM1500292; WLN: T6NJ B2 DYZUS; SPBio_001087; SPBio_002432; BPBio1_000563; Ethionamide (JP17/USP/INN); DTXSID0020577; AEOCXXJPGCBFJA-UHFFFAOYSA-; CTK3J2408; HMS500H07; KBio1_000145; KBio2_001562; KBio2_004130; KBio2_006698; KBio3_001236; KS-00000FAO; .alpha.-Ethyl-thioisonicotinamide; Isonicotinamide, 2-ethyl, thio-; NINDS_000145; HMS1569J13; HMS1920M22; HMS2091F03; HMS2096J13; HMS2231F10; HMS2233J11; HMS3259K17; HMS3370I18; HMS3371D12; HMS3655M10; HMS3713J13; Pharmakon1600-01500292; BCP29626; HY-B0276; ZINC3872520; Tox21_110458; Tox21_202409; Tox21_302769; ANW-42028; CCG-40212; FCH919543; GA6196; LS-199; NSC757028; s1777; SBB055548; AKOS006220662; Tox21_110458_1; CS-2266; DB00609; FS-1770; MCULE-1322319906; NC00508; NSC-757028; RTC-061432; IDI1_000145; NCGC00016497-01; NCGC00016497-02; NCGC00016497-03; NCGC00016497-04; NCGC00016497-06; NCGC00016497-08; NCGC00016497-09; NCGC00091074-01; NCGC00091074-02; NCGC00091074-03; NCGC00091074-04; NCGC00256600-01; NCGC00259958-01; AC-13715; CC-27545; M381; SAM002554899; SMR001370750; SBI-0051377.P003; AB0015183; AB2000288; AX8010649; DB-049945; TC-061432; AB00051990; ST24046699; ST50949989; SW196973-3; C07665; D00591; 2-ethylthioisonicotinamide; Trecator SC; Amidazine; 33010-EP2286812A1; 33010-EP2287165A2; 33010-EP2287166A2; 33010-EP2292620A2; 33010-EP2297130A1; 33010-EP2301536A1; 33010-EP2301538A1; 33010-EP2305675A1; 33010-EP2305695A2; 33010-EP2305696A2; 33010-EP2305697A2; 33010-EP2305698A2; 33010-EP2305808A1; 33010-EP2308833A2; 33010-EP2308852A1; 33010-EP2308874A1; 33010-EP2311455A1; 33010-EP2311815A1; 73833-EP2308926A1; 73833-EP2309564A1; AB00051990-09; AB00051990_10; AB00051990_11; A829694; C-04805; Q414767; SR-01000759219-2; SR-01000759219-5; BRD-K33710385-001-05-4; BRD-K51207550-001-09-9; Ethionamide, European Pharmacopoeia (EP) Reference Standard; Ethionamide, United States Pharmacopeia (USP) Reference Standard; Ethionamide for system suitability, European Pharmacopoeia (EP) Reference Standard; InChI=1/C8H10N2S/c1-2-7-5-6(8(9)11)3-4-10-7/h3-5H,2H2,1H3,(H2,9,11); Trecator; 2-Ethylthioisonicotinamide; Ethinamide; Ethioniamide; Trecator SC; Trecator-SC; Ethionamide [USAN:USP:INN:BAN:JAN]; F.I. 58-30
Ethosuximide 3-Ethyl-3-methyl-2,5-pyrrolidinedione; ethosuximide; 77-67-8; Zarontin; Etosuximida; 2-Ethyl-2-methylsuccinimide; Ethosuxide; Ethosuccimide; Ethosuccinimide; Petnidan; Suxinutin; Atysmal; Emeside; Ethymal; Suxilep; Etosuximid; Pentinimid; Peptinimid; Petinimid; Pyknolepsinum; Succimitin; Zaraondan; Capitus; Mesentol; Pemalin; Simatin; Succimal; Suximal; Thetamid; Zarodan; Zarondan; Zartalin; Asamid; Etomal; Pemal; Ronton; Suxin; 3-Ethyl-3-methylpyrrolidine-2,5-dione; Aethosuximide; Piknolepsin; Thilopemal; Epileo Petit MAL; Zarondan-Saft; Simatin(E); Ethosuximidum; 3-Methyl-3-ethylsuccinimide; 2-Methyl-2-ethylsuccinimide; Aethosuccimidum; Etosuximide; 2,5-Pyrrolidinedione, 3-ethyl-3-methyl-; CI-366; Succinimide, 2-ethyl-2-methyl-; 3-Ethyl-3-methylsuccinimide; 3-Ethyl-3-methyl-2,5-pyrrolidinedione; PM 671; PM-671; Etosuccimide [DCIT]; 3-Methyl-3-ethylpyrrolidine-2,5-dione; alpha-Ethyl-alpha-methylsuccinimide; alpha-Methyl-alpha-ethylsuccinimide; Aethosuximide [German]; gamma-Methyl-gamma-ethyl-succinimide; CN-10,395; N-Ethyl methylsuccinimide; Ethosuximidum [INN-Latin]; Etosuximida [INN-Spanish]; C.I. 366; H 940; H-490; Cl 366; (+-)-2-Ethyl-2-methylsuccinimide; CN-10395; HSDB 1119; gamma-ethyl-gamma-methyl-succinimide; EINECS 201-048-7; CI 366; NSC 64013; NSC-64013; 3-Ethyl-3-methylpyrroline-2,5-dione; CHEMBL696; .alpha.-Ethyl-.alpha.-methylsuccinimide; BRN 0117054; 3-ethyl-3-methyl-pyrrolidine-2,5-dione; CHEBI:4887; HAPOVYFOVVWLRS-UHFFFAOYSA-N; NSC64013; .gamma.-Methyl-.gamma.-ethylsuccinimide; Ethosuccimid; Etosuccimide; Suksilep; DSSTox_CID_3019; DSSTox_RID_76832; DSSTox_GSID_23019; Ethylmethylsuccimide; 2,5-Pyrrolidinedione, 3-ethyl-3-methyl-, (+-)-; Pyknole.psi.num; Piknole.psi.n; Zarontin (TN); SR-01000075863; Ethosuximide [USAN:INN:BAN:JAN]; CAS-77-67-8; NCGC00016320-01; Prestwick_611; Zorontin,Ethosuximide; Ethosuximide [USAN:USP:INN:BAN:JAN]; Spectrum_001385; Prestwick0_000165; Prestwick1_000165; Prestwick2_000165; Prestwick3_000165; Spectrum2_001483; Spectrum3_000944; Spectrum4_001051; Spectrum5_001073; E0746; (.+/-.)-Ethosuximide; 2, 3-ethyl-3-methyl-; E 7138; NCIOpen2_000014; Lopac0_000532; SCHEMBL34212; BSPBio_000029; KBioGR_001342; KBioSS_001865; 5-21-09-00595 (Beilstein Handbook Reference); DivK1c_000218; SPECTRUM1502196; SPBio_001465; SPBio_001950; BPBio1_000033; GTPL7182; WLN: T5VMVTJ D2 D1; DTXSID7023019; SCHEMBL20541518; CTK8B3160; Ethosuximide (JP17/USP/INN); Ethosuximide, analytical standard; HMS500K20; KBio1_000218; KBio2_001865; KBio2_004433; KBio2_007001; KBio3_002008; AOB5337; NINDS_000218; HMS1568B11; HMS1921L14; HMS2092D20; HMS2095B11; HMS3261L05; HMS3712B11; Pharmakon1600-01502196; HY-B1378; Ethosuximide 1.0 mg/ml in Methanol; Tox21_110370; Tox21_500532; (+/-)-2-ethyl-2-methylsuccinimide; ANW-41860; BDBM50240424; CCG-39217; MFCD00072123; NSC758192; s4626; 3-ethyl-3-methylazolidine-2,5-dione; AKOS005261742; Tox21_110370_1; CS-7976; DB00593; LP00532; MCULE-4034034545; NE54559; NSC-758192; SDCCGSBI-0050515.P004; .alpha.-Methyl-.alpha.-ethylsuccinimide; IDI1_000218; NCGC00015418-02; NCGC00015418-03; NCGC00015418-04; NCGC00015418-05; NCGC00015418-06; NCGC00015418-08; NCGC00015418-09; NCGC00093923-01; NCGC00093923-02; NCGC00093923-03; NCGC00093923-04; NCGC00261217-01; 3-Ethyl-3-methyl-2, 5-pyrrolidinedione; AS-16859; SC-65415; SBI-0050515.P003; 2, 5-Pyrrolidinedione, 3-ethyl-3-methyl-; LS-147585; AB00052288; AK01050738; EU-0100532; FT-0668060; ST51037248; C07505; D00539; AB00052288_04; zarontin3-Ethyl-3-methyl-pyrrolidine-2,5-dione; Q421567; SR-01000075863-1; SR-01000075863-3; SR-01000075863-5; W-109273; 3-Ethyl-3-methyl-pyrrolidine-2,5-dione(Ethosuximide); BRD-A99633051-001-04-7; BRD-A99633051-001-05-4; 3-Ethyl-3-methyl-pyrrolidine-2,5-dione (ethosuximide); Z2379802739; 3-ethyl-5-hydroxy-3-methyl-3,4-dihydro-2H-pyrrol-2-one; 4-ethyl-5-hydroxy-4-methyl-3,4-dihydro-2H-pyrrol-2-one; Ethosuximide, European Pharmacopoeia (EP) Reference Standard; Ethosuximide, United States Pharmacopeia (USP) Reference Standard; Ethosuximide solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material; N-(4-fluorobenzyl)-5-hydroxy-1-methyl-2-(2-(2-methyl-1,3,4-oxadiazole-5-carboxamido)propan-2-yl)-6-oxo-1,6-dihydropyrimidine-4-carboxamide; Ethosuximide; C.I. 366
Ethotoin 3-Ethyl-5-phenyl-2,4-imidazolidinedione; ethotoin; Peganone; 86-35-1; 3-Ethyl-5-phenylhydantoin; 3-ethyl-5-phenylimidazolidine-2,4-dione; Ethotoine; Ethotoinum; Etotoina; Ethotoine [INN-French]; Ethotoinum [INN-Latin]; Etotoina [INN-Spanish]; 3-Ethyl-5-phenylimidazolidin-2,4-dione; 1-Ethyl-2,5-dioxo-4-phenylimidazolidine; 2,4-Imidazolidinedione, 3-ethyl-5-phenyl-; Hydantoin, 3-ethyl-5-phenyl-; (+-)-3-Ethyl-5-phenylhydantoin; 3-ethyl-5-phenyl-imidazolidine-2,4-dione; HSDB 3580; EINECS 201-665-1; BRN 0188272; 3-Ethyl-5-phenyl-2,4-imidazolidinedione; CHEBI:4888; Accenon; Pegoanone; 2,4-Imidazolidinedione, 3-ethyl-5-phenyl-, (+-)-; Ethotoin [INN:BAN:JAN]; Peganone (TN); Accenon (TN); Ethotoin (JAN/USP/INN); Ethotoin [USP:INN:BAN:JAN]; CAS-86-35-1; NCGC00016340-01; (.+/-.)-Ethotoin; Prestwick0_000696; Prestwick1_000696; Prestwick2_000696; Prestwick3_000696; DSSTox_CID_3020; CHEMBL1095; DSSTox_RID_76833; DSSTox_GSID_23020; Oprea1_374844; SCHEMBL34301; BSPBio_000851; 5-24-08-00005 (Beilstein Handbook Reference); MLS002153961; SPBio_002772; ETHOTOIN (200 MG); BPBio1_000937; GTPL7183; DTXSID6023020; SZQIFWWUIBRPBZ-UHFFFAOYSA-N; HMS1570K13; HMS2097K13; HMS2232M06; HMS3371O03; HMS3714K13; Pharmakon1600-01505428; (+/-)-3-ethyl-5-phenylhydantoin; Tox21_110383; NSC760074; AKOS008947805; CCG-213433; DB00754; MCULE-6544505383; NSC-760074; NCGC00179401-01; NCGC00179401-03; LS-76194; NS-02146; SMR001233300; 3-Ethyl-5-phenyl-2,4-imidazolidinedione #; AB00513897; C07839; D00708; AB00513897_07; SR-01000841832; Q4533122; SR-01000841832-2; Z53845223; 1-ethyl-2-hydroxy-4-phenyl-4,5-dihydro-1H-imidazol-5-one; Ethotoin; 5-24-08-00005 (Beilstein Handbook Reference)
Ethoxzolamide 6-Ethoxy-2-benzothiazolesulfonamide; Ethoxzolamide; U-4191
Ethyl 3,4-dihydroxybenzoate 3,4-Dihydroxybenzoic acid, Ethyl ester; Ethyl protocatechuate; EINECS 223-529-0
Ethyl acetoacetate 3-Oxobutanoic acid, Ethyl ester; Ethyl acetoacetate; Acetoacetic acid, ethyl ester
Ethyl isocyanide Isocyanoethane; Ethyl isocyanide; Isocyanoethane; 624-79-3; Ethylcarbylamine; Ethyl isonitrile; Ethane, isocyano-; Ethylisokyanid [Czech]; Ethylkarbylamin [Czech]; Carbylamine, ethyl-; EINECS 210-863-7; Ethane, isocyano- (9CI); Ethyl isocyanide (8CI); CTK2F4241; DTXSID90977959; ISN-0734; ZX-BK001907; BBL021349; KM0617; STK894061; ZINC59134445; AKOS005144117; LS-52267; InChI=1/C3H5N/c1-3-4-2/h3H2,1H; Ethyl isocyanide; EINECS 210-863-7
Ethylene glycol monoethyl ether 2-Ethoxyethanol; 2-Ethoxyethanol; Cellosolve; 110-80-5; Oxitol; ETHYLENE GLYCOL MONOETHYL ETHER; Ethyl cellosolve; Ethanol, 2-ethoxy-; Ethyl glycol; Emkanol; Hydroxy ether; Ethylene glycol ethyl ether; Dowanol EE; Cellosolve solvent; 2-Ethoxyethyl alcohol; Plastiazan 60; Poly-Solv EE; Solvid; Ethylethylene glycol; EGEE; Jeffersol EE; Glycol monoethyl ether; 2-Ethoxyethan-1-Ol; beta-Ethoxyethanol; Bikanol E 1; Solvulose; Etoksyetylowy alkohol; Ektasolve EE; Dowanol 8; Celosolv; Ethyl ethylene glycol; Glycol ether EE; Celosolv [Czech]; Ethoxyethanol, 2-; NCI-C54853; .beta.-Ethoxyethanol; HSDB 54; Ethyl icinol; Ether monoethylique de l'ethylene-glycol; EE solvent; HOCH2CH2OC2H5; 2-ethoxy-ethanol; Athylenglykol-monoathylather; UNII-IDK7C2HS09; 2-Ethoxy ethanol; NSC 8837; Etoksyetylowy alkohol [Polish]; CCRIS 2294; Ethylene glycol monoethyl ether (EGMEE); Eter monoetilico del etilenglicol; ZNQVEEAIQZEUHB-UHFFFAOYSA-N; EINECS 203-804-1; Athylenglykol-monoathylather [German]; UN1171; Ethyl-2-hydroxyethyl ether; RCRA waste no. U359; IDK7C2HS09; AI3-01236; Eter monoetilico del etilenglicol [Spanish]; DTXSID7024087; CHEBI:46788; Ether monoethylique de l'ethylene-glycol [French]; DSSTox_CID_4087; DSSTox_RID_77284; DSSTox_GSID_24087; ETX; 2-Ethoxyethanol, for analysis; Ethylene glycol monoethyl ether [UN1171] [Flammable liquid]; 2-Ethoxyethanol, 99%, extra pure; 2EE; CAS-110-80-5; 2-Ethoxyethanol (cellosolve); 2ethoxyethanol; ethylene glycol-monoethyl ether; 2-ethoxyetanol; 2-Ehoxyethanol; 2-ethyoxyethanol; Cellosolve(R); Bikanol E1; ethoxyethyl alcohol; 1-ethoxy-2-ethanol; EtOCH2CH2OH; ethyl 2-hydroxyethyl ether; EC 203-804-1; ethyleneglycol monoethylether; ethylene glycol monoethylether; ethyleneglycol monoethyl ether; KSC177I6P; WLN: Q2O2; BIDD:ER0296; ACMC-20997c; CHEMBL119596; ethylene glycol mono ethyl ether; CTK0H7467; 2-Ethoxyethanol, ~99% (GC); 2-Ethoxyethanol, LR, >=99%; dimethylene glycol monoethyl ether; NSC8837; KS-00000WI8; NSC-8837; ZINC1648262; 2-Ethoxyethanol, analytical standard; Tox21_201697; Tox21_300031; ANW-16198; LS-515; MFCD00002869; STL282734; AKOS000119042; DB02249; MCULE-4311513289; RTR-032028; TRA0006364; 2-Ethoxyethanol, for synthesis, 99.0%; 2-Ethoxyethanol, ReagentPlus(R), 99%; NCGC00091522-01; NCGC00091522-02; NCGC00091522-03; NCGC00254064-01; NCGC00259246-01; BP-31042; SC-57903; TR-032028; E0047; FT-0626330; Ethylene Glycol Monoethyl Ether Reagent Grade; 2-Ethoxyethanol, SAJ first grade, >=97.0%; C14687; 2-Ethoxyethanol, SAJ special grade, >=99.0%; 73915-EP2269986A1; 73915-EP2272849A1; 73915-EP2275469A1; 73915-EP2287940A1; 73915-EP2289965A1; 73915-EP2298828A1; 73915-EP2301983A1; 73915-EP2302003A1; 73915-EP2308926A1; 73915-EP2309564A1; 73915-EP2371809A1; 73915-EP2380568A1; 73915-EP2380873A1; 74375-EP2270895A2; 74375-EP2278637A1; 74375-EP2281821A1; 74375-EP2298828A1; 74375-EP2299785A1; 74375-EP2305667A2; 74375-EP2305825A1; 74375-EP2306788A1; 74375-EP2306789A1; 74375-EP2308857A1; 74375-EP2380568A1; 2-Ethoxyethanol, spectrophotometric grade, >=99%; Q209381; J-509307; Ethyleneglycol-monoethyl ether 100 microg/mL in Methanol; F1908-0123; Z940713552; Ethylene glycol monoethyl ether [UN1171] [Flammable liquid]; InChI=1/C4H10O2/c1-2-6-4-3-5/h5H,2-4H2,1H; 2-Ethoxyethanol, Pharmaceutical Secondary Standard; Certified Reference Material; Ethanol, 2-ethoxy-; AI3-01236
Ethylestrenol (17alpha)-19-Norpregn-4-en-17-ol; ethylestrenol; Maxibolin; Orabolin; Neodurabolin; Duraboral; Maxibalin; Orgabolin; Orgaboral; Durabolin-O; Ethylnandrol; Ethylestrenolum; Etilestrenol; Ethyloestrenolum; Ethyloestrenol; Etilestrenolo [DCIT]; UNII-ADC79EK5Q8; 17alpha-Ethylestr-4-en-17beta-ol; Etilestrenol [INN-Spanish]; 965-90-2; Ethylestrenolum [INN-Latin]; 17alpha-Ethyl-17beta-hydroxy-4-estrene; 19-Nor-17alpha-pregn-4-en-17beta-ol; 19-Norpregn-4-en-17-ol, (17alpha)-; HSDB 3327; EINECS 213-523-6; Estr-4-en-17beta-ol, 17-ethyl-; NSC 37726; 17beta-Hydroxy-17alpha-ethyl-19-nor-4-androstene; ADC79EK5Q8; (17-alpha)-19-Norpregn-4-en-17-ol; CHEBI:31578; (17alpha)-19-norpregn-4-en-17-ol; 19-Nor-17-alpha-pregn-4-en-17-ol; NCGC00167514-01; ORG-483; DSSTox_CID_3024; DSSTox_RID_76835; DSSTox_GSID_23024; Etilestrenolo; (17beta)-17-ethylestr-4-en-17-ol; CAS-965-90-2; SMR000238204; Ethylestrenol [USAN:INN]; Ethylestrenol [USAN:INN:BAN]; Orabolin (TN); Ethylnandrol (JAN); Ethylestrenol (USAN/INN); MLS000759411; MLS001424123; SCHEMBL147908; GTPL6948; CHEMBL1200623; DTXSID6023024; HMS2051P08; ZINC4215863; Tox21_112512; 19-Nor-17alpha-pregn-4-en-17-ol; Tox21_112512_1; API0002632; CCG-101014; DB01493; NC00264; NCGC00167514-02; (8R,9S,10R,13S,14S,17S)-17-ethyl-13-methyl-2,3,6,7,8,9,10,11,12,14,15,16-dodecahydro-1H-cyclopenta[a]phenanthren-17-ol; LS-97392; 19-Norpregn-4-en-17-ol, (17-alpha)-; 19-Nor-17alpha-pregn-4-en-17-ol (8CI); D01414; Q764283; 19-Norpregn-4-en-17-ol, (17-alpha)- (9CI); Ethylestrenol; Durabolin-O
Etidronic acid Phosphonic acid, (1-hydroxyethylidene)bis-; Etidronic acid; 1000SL
Etodolac etodolac; 41340-25-4; Etodolic acid; Lodine; Ultradol; Lodine XL; Etodolaco; Etodolacum; Ramodar; AY 24236; Etodolacum [INN-Latin]; Etodolaco [INN-Spanish]; AY-24236; AY-24,236; Edolan; CCRIS 3923; 1,3,4,9-Tetrahydro-1,8-diethylpyrano(3,4-b)indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; 2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid; Pyrano[3,4-b]indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-; 2-(1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid; CHEMBL622; NSC 282126; 1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid; (1,8-Diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl)acetic acid; MLS000028474; CHEBI:4909; RAK-591; NNYBQONXHNTVIJ-UHFFFAOYSA-N; (1,8-Diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indol-1-yl)-acetic acid; Pyrano(3,4-b)indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-; NSC282126; NSC-282126; SMR000058443; DSSTox_CID_615; 2-{1,8-diethyl-1H,3H,4H,9H-pyrano[3,4-b]indol-1-yl}acetic acid; (+-)-1,8-Diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; DSSTox_RID_75691; DSSTox_GSID_20615; Hypen; 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-ylacetic acid; Pyrano(3,4-b)indole-1-acetic acid, 1,3,4,9-tetrahydro-1,8-diethyl-; Pyrano(3,4-b)indole-1-acetic acid, 1,8-diethyl-1,3,4,9-tetrahydro-(+-)-; SR-01000000100; Etodolac [USAN:INN:BAN]; Osteluc; Tedolan; Zedolac; etodolac o; rac-Etodolac; Etodlic Acid; [1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl]acetic acid; Etodolac(Lodine); Lodine SR; KS-1056; Etodolac [USAN:USP:INN:BAN]; NCGC00016849-01; Etodolac,(S); Prestwick_209; CAS-41340-25-4; Lodine (TN); Spectrum_001244; Opera_ID_1774; Prestwick0_000231; Prestwick1_000231; Prestwick2_000231; Prestwick3_000231; Spectrum2_001387; Spectrum3_001429; Spectrum4_000410; Spectrum5_001347; SCHEMBL3903; Lopac0_000479; BSPBio_000301; BSPBio_003138; KBioGR_000680; KBioSS_001724; MLS001077315; MLS006011566; DivK1c_000147; SPECTRUM1501005; Etodolac (JP17/USP/INN); SPBio_001374; SPBio_002222; BPBio1_000333; GTPL7185; DTXSID9020615; CTK4I4719; HMS500H09; KBio1_000147; KBio2_001724; KBio2_004292; KBio2_006860; KBio3_002358; NINDS_000147; HMS1568P03; HMS1921B09; HMS2092O20; HMS2095P03; HMS2231D04; HMS3259P10; HMS3261O20; HMS3374G09; HMS3712P03; Pharmakon1600-01501005; BCP28411; NIH-9918; Tox21_110644; Tox21_202218; Tox21_500479; ANW-42024; BDBM50016799; CCG-39005; CE0096; MFCD00133313; NSC757821; AKOS015838610; Tox21_110644_1; AC-4231; CS-0832; DB00749; LP00479; LS-7393; NC00718; NSC-757821; RTR-036749; SDCCGSBI-0050463.P004; IDI1_000147; KS-0000000W; NCGC00015399-03; NCGC00015399-04; NCGC00015399-05; NCGC00015399-06; NCGC00015399-07; NCGC00015399-08; NCGC00015399-09; NCGC00015399-11; NCGC00015399-12; NCGC00015399-13; NCGC00015399-15; NCGC00015399-16; NCGC00089769-02; NCGC00089769-03; NCGC00089769-04; NCGC00089769-05; NCGC00089769-06; NCGC00089769-07; NCGC00259767-01; NCGC00261164-01; AK550845; CPD000058443; HY-76251; SAM002589968; SBI-0050463.P003; AB0012214; AY-24-236; TR-036749; AB00052194; E0858; EU-0100479; FT-0607046; C06991; D00315; E 0516; K-8734; Pyrano[3, 1,8-diethyl-1,3,4,9-tetrahydro-; AB00052194_17; 340E254; Q-201099; Q2465218; SR-01000000100-2; SR-01000000100-4; SR-01000000100-7; BRD-A74667430-001-05-3; BRD-A74667430-001-15-2; 1,3,4,9-tetrahydropyrano[3,4-b]indole-1-acetic acid; Etodolac, European Pharmacopoeia (EP) Reference Standard; F2173-0681; Z1820178466; Etodolac, United States Pharmacopeia (USP) Reference Standard; 1,8-diethyl-1,3,4,9-tetrahydro-pyrano[3,4-b]indole-1-acetic acid; 1,8-Diethyl-1,3,4,9-tetrahydropyranol[3,4-b]indole-1-acetic acid; (+/-)-1,8-diethyl-1,3,4,9-tetrahydropyrano(3,4-b)indole-1-acetic acid; (RS)-2-(1,8-Diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid; 2-(1,8-diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid.; Pyrano(3,4,b)indole-1-acetic acid, 1,3,4,9-tetrahydro-1,8-diethyl-; AY 24,236; AY 24236; AY-24,236; AY-24236; AY24,236; AY24236; Etodolac for peak identification, European Pharmacopoeia (EP) Reference Standard; AY 24236
Etoposide [5R-[5-alpha, 5a-beta, 8a-alpha, 9-beta(R*)]]-9-[(4,6-O-Ethylidene-beta-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenylfuro[3',4':6,7]naphtho[2,3-d]-dioxol-6(5aH )-one; Etoposide; CCRIS 2392
Eucalyptol 1,3,3-Trimethyl-2-oxabicyclo[2.2.2]octane; Eucalyptol; cineole; 1,8-Cineole; 1,8-Cineol; 470-82-6; Cajeputol; 1,8-Epoxy-p-menthane; Zineol; Eucalyptole; Eucapur; Terpan; p-Cineole; 1,3,3-Trimethyl-2-oxabicyclo[2.2.2]octane; 1,8-Oxido-p-menthane; Eukalyptol; CINEOL; Cucalyptol; Eukalyptol [Czech]; Eucalyptol (natural); Zedoary oil; p-Menthane, 1,8-epoxy-; 2-Oxabicyclo[2.2.2]octane, 1,3,3-trimethyl-; Cineole (VAN); FEMA No. 2465; Eucalyptol [USAN]; NCI-C56575; UNII-RV6J6604TK; 2-Oxabicyclo(2.2.2)octane, 1,3,3-trimethyl-; NSC 6171; 1,3,3-Trimethyl-2-oxabicyclo(2.2.2)octane; 2-Oxa-1,3,3-trimethylbicyclo(2.2.2)octane; Eucalyptol (USAN); CCRIS 3727; HSDB 991; Cineole (Eucalyptol); NSC6171; 2,2,4-trimethyl-3-oxabicyclo[2.2.2]octane; 2-Oxa-1,3,3-trimethylbicyclo[2.2.2]octane; EINECS 207-431-5; MFCD00167977; AI3-00578; RV6J6604TK; CNL; Soledum; 4,7,7-trimethyl-8-oxabicyclo[2.2.2]octane; CHEBI:27961; WEEGYLXZBRQIMU-UHFFFAOYSA-N; NSC-6171; NCGC00091666-01; NCGC00091666-04; EUCALYPTUS OIL; DSSTox_CID_616; 1,8-Cineole, 99%; DSSTox_RID_75692; DSSTox_GSID_20616; W-106080; (1s,4s)-1,3,3-trimethyl-2-oxabicyclo[2.2.2]octane; Eucalyptol 1000 microg/mL in Methanol; CAS-470-82-6; SMR000471853; Eucalyptol [USAN:USP]; 8000-48-4; BIDD:ER0481; Eucalyptol,(S); 1.8-cineole; Eucalyptol, 99%; Eucalyptol, Ph Helv; p-Menthane,8-epoxy-; 1,8-Cineol; WLN: T66 A B AOTJ B1 B1 F1; Spectrum2_000221; Spectrum3_000683; Spectrum4_001747; Spectrum5_000704; bmse000523; EC 207-431-5; SCHEMBL19622; SCHEMBL41020; BSPBio_002405; KBioGR_002194; MLS001050089; MLS001066338; DivK1c_000333; SPECTRUM1500294; SPBio_000261; Eucalyptol, analytical standard; CHEMBL485259; GTPL2464; CHEMBL1231862; CHEMBL1397305; DTXSID4020616; SCHEMBL13554591; SCHEMBL17836873; CTK6B3326; HMS501A15; KBio1_000333; KBio3_001625; NINDS_000333; HMS2271P04; Pharmakon1600-01500294; ZINC967566; HY-N0066; Tox21_111161; Tox21_202090; Tox21_302902; 5750AF; CCG-36080; LS-128; NSC760388; SBB057535; Acylated oxime isatin derivative, 19; AKOS015903223; AKOS016034339; AKOS037514637; Tox21_111161_1; CS-8146; DB03852; FCH1679459; LMPR0102090019; NSC-760388; IDI1_000333; Eucalyptol, tested according to Ph.Eur.; NCGC00091666-02; NCGC00091666-03; NCGC00091666-05; NCGC00095774-01; NCGC00178671-01; NCGC00256479-01; NCGC00259639-01; AC-20234; Eucalyptol, natural, >=99%, FCC, FG; NCI60_005108; SC-47256; ST096004; 1,3-Trimethyl-2-oxabicyclo[2.2.2]octane; 2-Oxa-1,3-trimethylbicyclo[2.2.2]octane; DB-070775; TR-017465; 2-Oxabicyclo[2.2.2]octane,3,3-trimethyl-; FT-0607033; FT-0626369; 1,3,3-trimethyl-2-oxabicyclo[2,2,2]octane; 1,3,3-trimethyl-2-oxabicyclo[2.2.2]octan; A15662; A19469; C09844; D04115; AB01563262_01; Q161572; SR-01000763816; SR-01000763816-2; 1,8-Cineole, primary pharmaceutical reference standard; Cineole, European Pharmacopoeia (EP) Reference Standard; Eucalyptol, certified reference material, TraceCERT(R); F0001-1260; Eucalyptol, United States Pharmacopeia (USP) Reference Standard; Eucalyptol (cineole), Pharmaceutical Secondary Standard; Certified Reference Material; InChI=1/C10H18O/c1-9(2)8-4-6-10(3,11-9)7-5-8/h8H,4-7H2,1-3H; Cajeputol; AI3-00578
Euflavine Euflavine B
Excenel (6R,7R)-7-[[(2Z)-2-(2-Amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-3-[[(2-furanylcarbonyl)thio]methyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid; Ceftiofur; Ceftiofur
Exemestane 6-Methyleneandrosta-1,4-diene-3,17-dione; EXEMESTANE; 107868-30-4; Aromasin; 6-Methyleneandrosta-1,4-diene-3,17-dione; Fce 24304; Exemestano; Exemestanum; Exemestanum [INN-Latin]; Exemestano [INN-Spanish]; FCE-24304; 6-Methylene-androsta-1,4-diene-3,17-dione; Exemestane [USAN:INN:BAN]; UNII-NY22HMQ4BX; Androsta-1,4-diene-3,17-dione, 6-methylene-; HSDB 7463; 6-methylideneandrosta-1,4-diene-3,17-dione; FCE24304; Aromasine; NY22HMQ4BX; PNU-155971; 6-Methylenandrosta-1,4-diene-3,17-dione; CHEBI:4953; (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylene-7,8,9,10,11,12,13,14,15,16-decahydro-3H-cyclopenta[a]phenanthrene-3,17(6H)-dione; (8R,9S,10R,13S,14S)-10,13-dimethyl-6-methylidene-7,8,9,11,12,14,15,16-octahydrocyclopenta[a]phenanthrene-3,17-dione; Aromasil; MFCD00866994; NSC713563; EXE; DSSTox_CID_3037; DSSTox_RID_76844; DSSTox_GSID_23037; Nikidess; (8alpha,10alpha,13alpha)-6-Methylideneandrosta-1,4-Diene-3,17-Dione; Aromasin (TN); SMR000466314; CAS-107868-30-4; Curator_000009; Exemestane (JAN/USP/INN); CCRIS 9351; NCGC00095289-01; (8R,9S,10R,13S,14S)-10,13-Dimethyl-6-methylene-7,8,9,11,12,13,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17(10H,14H)-dione; CPD000466314; Exemestane, Aromasin; PNU 155971; PubChem5810; SCHEMBL6215; Aromasin (Pharmacia Upjohn); Exemestane(FCE 24304); MLS000759419; MLS001424062; GTPL7073; 6-Methylenandrosta-1,17-dione; CHEMBL1200374; DTXSID5023037; Exemestane, >=98% (HPLC); CTK0H9416; AOB5604; SYN3023; BFYIZQONLCFLEV-DAELLWKTSA-N; BCPP000235; HMS2051J04; HMS3713H12; BCP23353; ZINC3973334; Tox21_111499; ANW-63402; BDBM50398447; s1196; AKOS015840113; AKOS015895161; Tox21_111499_1; AC-2171; BCP9000676; CCG-100995; CS-1766; DB00990; KS-5136; NC00245; NSC-713563; NCGC00271596-03; 6-methylenandrost-1,4-dien-3,17-dione; AS-31053; CC-28344; HY-13632; LS-19329; SC-46568; BCP0726000226; 6-Methylen-androst-1,4-diene-3,17-dione; AB0063735; TC-152147; E0941; C08162; D00963; Z-4332; AB00639936-06; AB00639936-08; AB00639936-09; AB00639936-10; AB00639936_11; 868E304; C-18573; Q418819; SR-01000759393; SR-01000759393-4; BRD-K33425534-001-12-5; Exemestane, European Pharmacopoeia (EP) Reference Standard; Exemestane, United States Pharmacopeia (USP) Reference Standard; Exemestane, Pharmaceutical Secondary Standard; Certified Reference Material; Exemestane for system suitability, European Pharmacopoeia (EP) Reference Standard; (1S,2R,10R,11S,15S)-2,15-dimethyl-8-methylidenetetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-3,6-diene-5,14-dione; EXM; Exemestane [USAN:INN:BAN]; Exemestano [INN-Spanish]
Felbamate felbamate; 25451-15-4; Felbatol; 2-Phenylpropane-1,3-diyl dicarbamate; 2-Phenyl-1,3-propanediol dicarbamate; Felbamyl; Taloxa; Felbamato; Felbamatum; W-554; Felbamatum [Latin]; Felbamato [Spanish]; 1,3-Propanediol, 2-phenyl-, dicarbamate; ADD-03055; Felbamate [USAN:INN]; W 554; UNII-X72RBB02N8; carbamic acid 2-phenyltrimethylene ester; CHEBI:4995; Carbamic acid, 2-phenyltrimethylene ester; EINECS 247-001-4; BRN 3345236; 3-(carbamoyloxy)-2-phenylpropyl carbamate; MLS000028465; X72RBB02N8; WKGXYQFOCVYPAC-UHFFFAOYSA-N; NCGC00015429-08; SMR000058448; DSSTox_CID_3041; DSSTox_RID_76847; DSSTox_GSID_23041; Carbamic acid 3-carbamoyloxy-2-phenyl-propyl ester; Q-100326; Felbatol (TN); CAS-25451-15-4; (3-carbamoyloxy-2-phenylpropyl) carbamate; SR-01000000089; Felbamate (USAN/INN); HSDB 7525; ADD 03055; Tocris-0869; Opera_ID_1738; Prestwick0_000919; Lopac-F-0778; Biomol-NT_000203; F 0778; CHEMBL1094; Lopac0_000524; SCHEMBL34947; 4-06-00-05993 (Beilstein Handbook Reference); MLS001077299; BIDD:GT0463; BPBio1_001258; GTPL5473; DTXSID9023041; AOB5042; EX-A591; HMS2093P19; HMS2234H06; HMS3261J09; HMS3266L12; HMS3370I06; HMS3411P21; HMS3657I11; HMS3675P21; HMS3715D20; Pharmakon1600-01505600; (3-carbamoyloxy-1,1,3,3-tetradeuterio-2-phenylpropyl) carbamate; BCP27941; HY-B0184; KS-00001F6O; ZINC1530803; Tox21_110145; Tox21_302368; Tox21_500524; 2-Phenyl-1,3-propanedioldicarbamate; ANW-65602; BDBM50088430; BN0583; MFCD00865296; NSC759866; s1330; AKOS015895100; Tox21_110145_1; AC-8197; ACN-054465; API0002680; CCG-204614; CS-2068; DB00949; KS-1171; LP00524; MCULE-2661497722; NSC-759866; SDCCGSBI-0050507.P003; NCGC00015429-01; NCGC00015429-02; NCGC00015429-03; NCGC00015429-04; NCGC00015429-05; NCGC00015429-06; NCGC00015429-07; NCGC00015429-09; NCGC00015429-10; NCGC00015429-11; NCGC00015429-14; NCGC00023092-02; NCGC00023092-04; NCGC00023092-05; NCGC00023092-06; NCGC00255275-01; NCGC00261209-01; CC-28364; SC-46002; SBI-0050507.P002; AB0011540; AB1008593; AX8130043; DB-046702; LS-120706; TC-154347; EU-0100524; FT-0630517; SW197633-2; (3-aminocarbonyloxy-2-phenyl-propyl) carbamate; C07501; D00536; EN300-119542; J90036; K-6677; AB00382985-18; AB00382985_19; 451F154; A817858; C-14192; Q421301; carbamic acid (3-carbamoyloxy-2-phenylpropyl) ester; SR-01000000089-2; SR-01000000089-4; SR-01000000089-7; BRD-K99107520-001-01-9; BRD-K99107520-001-09-2; BRD-K99107520-001-18-3; Z1541638522; Felbamate, United States Pharmacopeia (USP) Reference Standard; 2-?methyl-?4-?(4-?methyl-?1-?piperazinyl)-?10H-?thieno[2,?3-?b][1,?5]benzodiazepine; W 554
Fencamfamin N-Ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine; Fencamfamin; Fencamfamine; Fencamfaminum; Reactivan; Euvitol; Fenacamfamin; Fencamfamina [DCIT]; phencamphamine; Fencamfamine [INN-French]; Fencamfaminum [INN-Latin]; Fencanfamina [INN-Spanish]; 2-Ethylamino-3-phenylnorbornane; Fencamfamin [INN:BAN]; 1209-98-9; 3-Phenyl-N-ethyl-2-norbornanamine; Femcamfamine; UNII-NME1I5IGBK; 2-NORBORNANAMINE, N-ETHYL-3-PHENYL-; 2-Phenyl-3-ethylaminobicyclo(2.2.1)heptane; NME1I5IGBK; DEA No. 1760; N-Ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine; Bicyclo(2.2.1)heptan-2-amine, N-ethyl-3-phenyl-; FencamfamiFencanfamiN-ethyl-3-phenylbicyclo(2.2.1)heptan-2-amine; Fencamfamin (INN); 2-ethylamino-3-phenylnorcamphane; CHEMBL7010; SCHEMBL156977; CHEBI:134895; IKFBPFGUINLYQI-UHFFFAOYSA-N; DB01463; LS-97058; FT-0668483; D07343; N-Ethyl-3-phenylbicyclo[2.2.1]heptan-2-amine #; Q3742409; Fencamfamine; 2-Ethylamino-3-phenylnorbornane
Fenofibrate 2-[4-(4-Chlorobenzoyl)phenoxy]-2-methylpropanoic acid, 1-Methylethyl ester; Procetofen; BRN 2062462
Fenoprofen alpha-Methyl-3-phenoxybenzeneacetic acid; Fenoprofen; EINECS 249-770-1
Fenticonazole 1-[2-(2,4-Dichlorophenyl)-2-[[4-(phenylthio)phenyl]methoxy]ethyl]-1H-imidazole; FENTICONAZOLE; 72479-26-6; Fenticonazole [INN:BAN]; Fenticonazol [INN-Spanish]; Fenticonazolum [INN-Latin]; C24H20Cl2N2OS; 1-[2-(2,4-Dichlorophenyl)-2-[[4-(phenylthio)phenyl]methoxy]ethyl]-1H-imidazole; CHEBI:83602; Fenticonazol; Fenticonazolum; 1-(2-(2,4-Dichlorophenyl)-2-((4-(phenylthio)benzyl)oxy)ethyl)-1H-imidazole; 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]-1H-imidazole; 1H-Imidazole, 1-(2-(2,4-dichlorophenyl)-2-((4-(phenylthio)phenyl)methoxy)ethyl)-; Fenticonazole (INN); 1-[2-(2,4-dichlorophenyl)-2-[(4-phenylsulfanylphenyl)methoxy]ethyl]imidazole; DSSTox_CID_31601; DSSTox_RID_97485; DSSTox_GSID_57812; SCHEMBL147157; CHEMBL1651990; DTXSID7057812; ZCJYUTQZBAIHBS-UHFFFAOYSA-N; Rec 15-1476; ACT06284; Tox21_113832; STL452902; AKOS015897483; API0007259; DB13434; NCGC00253713-01; NCGC00253713-02; AC-15958; AS-48904; K232; CAS-72479-26-6; LS-176975; A9423; FT-0660865; D02582; AB01566883_01; 479F266; Q3068413; 1-(2,4-dichloro-beta-((p-(phenylthio)benzyl)oxy)phenethyl)imidazole; 1-(2-(2,4-dichlorophenyl)-2-(4-(phenylthio)benzyloxy)ethyl)-1H-imidazole; 1-(2-(4-(phenylthio)benzyloxy)-2-(2,4-dichlorophenyl)ethyl)-1H-imidazole; 1-[2-(2,4-dichlorophenyl)-2-{[4-(phenylsulfanyl)benzyl]oxy}ethyl]imidazole; 1-[2-(2,4-Dichlorophenyl)-2-{[4-(phenylsulfanyl)phenyl]methoxy}ethyl]-1H-imidazole; Fenticonazole; Fenticonazol [INN-Spanish]
Fisetin 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; Fisetin; 528-48-3; 5-Desoxyquercetin; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one; Cotinin; Fustel; Viset; 3,3',4',7-Tetrahydroxyflavone; Fisetholz; Superfustel; Fietin; Fustet; Junger fustik; 3,7,3',4'-Tetrahydroxyflavone; Ventin sumach; Young fustic; Zante fustic; Superfustel K; Ungarisches gelbholz; C.I. Natural Brown 1; Young fustic crystals; Bois bleu de Honqrie; BOIS bleude honqrie; C.I. 75620; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-; NSC 407010; NSC 656275; 5-Deoxyquercetin; Natural Brown 1; UNII-OO2ABO9578; 7,3',4'-Trihydroxyflavonol; BRN 0292829; CCRIS 9034; 2-(3,4-dihydroxyphenyl)-3,7-dihydroxychromen-4-one; EINECS 208-434-4; NSC407010; CHEMBL31574; OO2ABO9578; FLAVONE, 3,3',4',7-TETRAHYDROXY-; CHEBI:42567; XHEFDIBZLJXQHF-UHFFFAOYSA-N; TNP00284; MFCD00006829; NSC656275; 2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-chromen-4-one; NSC-407010; AK-88492; Q-100599; FSE; SR-05000002249; Fisetine; Fisetin (Fustel); Fisetin, 15; Spectrum_001196; 1xo2; SpecPlus_000460; Spectrum2_001160; Spectrum3_001536; Spectrum4_001070; Spectrum5_001797; NCIMech_000006; SCHEMBL39454; 3,3'4'7-tetOH-Flavone; 3,4',7-Tetrahydroxyflavone; BSPBio_002952; KBioGR_001400; KBioSS_001676; 5-18-05-00291 (Beilstein Handbook Reference); MLS006011782; 528-48-3 (anhydrous); BIDD:ER0141; DivK1c_006556; SPECTRUM1502247; SPBio_001119; BDBM7457; GTPL5182; DTXSID4022317; CTK8B4476; KBio1_001500; KBio2_001676; KBio2_004244; KBio2_006812; KBio3_002452; KS-00000YFR; ZINC39111; BIF1001; Flavone,3',4',7-tetrahydroxy-; ZX-AFC002753; HMS3604H03; HMS3655L22; ACT02610; HY-N0182; TNP00004; 3,3',4',7-Tetra-hydroxy-flavone; ANW-45197; BBL027612; CCG-35267; CF0050; LMPK12111566; MFCD04220857; s2298; SBB066118; STL146392; AKOS000277885; CS-7840; DB07795; MCULE-8216354240; NSC-656275; RTR-036986; SDCCGMLS-0066657.P001; 3,2',4',7-TETRAHYDROXYFLAVONE; NCGC00017344-01; NCGC00017344-02; NCGC00017344-03; NCGC00017344-04; NCGC00017344-05; NCGC00017344-06; NCGC00095663-01; NCGC00095663-02; NCGC00178374-01; ACM345909344; AS-15520; CC-28430; CI-75620; LS-69038; NCI60_003865; P707; SC-16989; SMR001835029; ST057233; AX8006342; ST2403855; FT-0613996; N2487; SW219914-1; 28F483; C10041; S00056; C-34894; Q418384; J-019667; SR-05000002249-2; SR-05000002249-3; 2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-chromone; dihydrate; 4H-1-Benzopyran-4-one,4-dihydroxyphenyl)-3,7-dihydroxy-; 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one #; 3,7-Dihydroxy-2-(3,4-dihydroxyphenyl)-4H-1-benzopyran-4-one; Fisetin; 5-Deoxyquercetin; 3,3?,4?,7-Tetra??hydroxy??flavone; Natural Brown 1; InChI=1/C15H10O6/c16-8-2-3-9-12(6-8)21-15(14(20)13(9)19)7-1-4-10(17)11(18)5-7/h1-6,16-18,20; Fisetin; C.I. 75620